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Abstract 
 
Targeted therapy and immunotherapy eradicate malignant cells through different 
mechanisms, and the strengths and weaknesses of these two approaches are potentially 
complementary. Therefore, the combination of molecular targeted drugs with immune-
based therapies is considered an attractive approach for improving the therapeutic 
efficacy of cancer treatment. The mutation and amplification of the c-KIT proto-
oncogene are associated with multiple different cancer types, and multiple c-KIT 
inhibitors have been tested clinically. In spite of some encouraging results using these 
agents, most patients with c-KIT mutant cancers still relapse due to drug resistance. This 
also demonstrates the inherent limitation of molecular targeted drugs as mono-therapies, 
and highlights the need for combinatorial therapeutic approaches. 
 
In this study, we show in the c-KIT mutant mastocytoma P815 mouse model that the 
therapeutic effect of the c-KIT inhibitor dasatinib is substantially dependent on the anti-
tumor T cell response. Even though the direct effect of dasatinib on antigen-driven T cell 
expansion is inhibitory, 3-day dasatinib treatment significantly increased the proportion 
of tumor-specific T cells in the circulation of the treated mice. We also found that 
dasatinib augmented the priming of T cells through inhibition of immunosuppressive 
components, including down-regulation of Treg cells and IL-10. When dasatinib was 
combined with anti-OX40, an agonistic antibody that provides T cells with a potent 
costimulatory signal, we found that the two agents together gave a much better 
therapeutic effect compared with either therapy alone, leading to complete tumor 
eradication in most of the treated mice. Anti-OX40 alone enhanced the infiltration of 
 vi 
CD8+ T cells within the tumor microenvironment. Furthermore, the combination of 
dasatinib and anti-OX40 significantly up-regulated the expression of  IFN-γ-induced Th1 
chemokines CXCL 9, 10 and 11, which was consistent with the enrichment of tumor-
specific T cells at the tumor sites and better therapeutic effect. This study demonstrates 
that combinations of molecular targeted agents with immunotherapeutic approaches may 
result in superior therapeutic effects, suggesting that employing a similar combination 
strategy  may provide clinical benefits to patients with c-KIT mutant cancers. 
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Chapter 1.  Introduction 
 
1.1 Targeted therapy of cancer 
 
Discoveries of  specific proteins and pathways that contribute to the carcinogenesis and 
malignant phenotype of cancer cells have led to the generation of therapeutic agents 
which can specifically target cancer cells. Unlike chemotherapy and radiation therapy, 
which commonly impair rapidly dividing cells, targeted therapy interferes with the 
specific pathways necessary for cancer progression and therefore it is considered more 
effective and less toxic than conventional treatments. Targeted therapy drugs include 
antibodies and small molecule inhibitors. Monoclonal antibodies target specific antigens 
either are extracellular growth factors or receptors on cell surface. Binding of the 
antibody with the ligand or the receptor could effectively block the activity of that 
specific oncogenic pathway.  Monoclonal antibodies which have achieved significant 
success in the clinic include anti-CD20(Rituximab), anti-VEGF(Bevacizumab), anti-
EGFR( Cetuximab) and anti-Her2/neu(Trastuzumab). Those monoclonal antibodies have 
been used for the treatment of various types of cancers, including breast cancer, 
lymphoma, colon cancer and lung cancer(1-5). Small molecule targeted therapy drugs are 
another class of agents discovered or structurally designed for oncogenic proteins.  
Compared with monoclonal antibodies, this class of drug is less specific because they 
normally affect a subset of kinases with similar structure on the targeted domain rather 
than block the activity of one target. But the advantage of small molecule inhibitors is 
their ability of interfering with intracellular molecules which monoclonal antibodies 
cannot(6). Multiple small molecule inhibitors have been approved by FDA for cancer 
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treatment, for example, erlotinib, gefenitib and vemurafenib. And more drugs are being 
tested in clinical and preclinical studies(7, 8). 
 
Advent of  molecularly targeted agents is considered as a milestone in the history of 
cancer therapy. However, the instability and complexity of cancer genome limit the 
success of targeted therapy. The responses to targeted therapy are usually of limited 
durability. A general phenomenon in patients is the development of drug resistance (9-
11). Multiple mechanisms are involved in the occurrence of drug resistance in patients:  
mutation of the target protein could reduce the binding affinity between the drug and the 
target; the expression of the target can be up-regulated at DNA, mRNA and protein levels; 
enhanced activities of other oncoproteins could compensate for the inhibition of the target 
protein; overexpression of the drug transporters could reduce the intracellular drug 
concentration; drug-resistant cancer cell clones could outgrow the drug-sensitive 
clones(12) . Therefore, it is unlikely that targeted therapy alone can lead to cure.  
 
1.2 C-KIT 
 
C-KIT (CD117) is a tyrosine kinase receptor, which is encoded by the proto-oncogene 
KIT located on human chromosome 4 and mouse chromosome 5.  Under physiological 
condition, this receptor is expressed by hematopoietic  stem  cells,  mast  cells,  melanocytes  
and   interstitial  cells  of  Cajal.  Its ligand is stem cell factor (SCF) which is secreted by 
endothelial cells and fibroblasts(13). The extracellular part of c-KIT is composed of five 
immunoglobulin-like domains, this is the ligand binding domain and is encoded by exon 
2-9. The juxtamembrane domain which is believed to have auto-inhibitory function is 
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encoded by exon 11. The intracellular part contains 2 tyrosine kinase domains, one ATP-
binding pocket encoded by exon 13 and 14 and one kinase activation loop encoded by 
exon17 (Figure 1)(14, 15). Upon the binding of SCF, 2 c-KIT receptors form a dimer and 
phosphorylate each other on certain tyrosine residues. The phosphorylated tyrosine 
residues serve as the docking sites for multiple effector molecules, then activate a wide 
array of downstream signal transduction pathways, including MAPK pathway, PI3K/Akt 
and JAK/STAT pathway, which play critical roles in multiple aspects of cellular 
functionality(16-18).  
 
The amplification and mutation of this gene are associated with several types of cancer, 
including gastrointestinal stromal tumors(GIST), mast cell leukemia, melanoma, 
testicular seminoma and acute myeloid leukemia. Mutation of c-KIT could cause the 
activation of this receptor without the binding of SCF, and the deregulated activation of 
downstream oncogenic pathways leads to the uncontrolled growth and survival of 
cells(19, 20). Therefore, c-KIT became an attractive target for the treatment of those 
cancers. And multiple c-KIT inhibitors have been developed and applied in clinical 
practice. 
 
GIST is derived from c-KIT expressing interstitial   cells   of   Cajal (ICC). Activating 
mutation of c-KIT has been found in more than 80% of GIST patients.  The most 
common genetic aberrations occurring in GIST are duplication of codon 502-503 on exon 
9 and V560G mutation on exon 11(13, 21, 22). The tumor is refractory to conventional 
chemotherapy and irradiation therapy. However, introduction of c-KIT inhibitors into the 
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clinic has significantly improved the prognosis of the patients and change the natural 
history of this disease. It is one of the most successful examples showing the 
effectiveness of molecular targeted therapy. Currently, imatinib is applied in the clinic for 
treating patients with unresectable tumors and patients after surgical removal for 
prevention purpose. Another c-KIT inhibitor sunitinib has been shown to be effective in 
treating GIST patients who have developed resistance to imatinib(23). 
 
Mutation of c-KIT in the overall melanoma population is at a relatively low frequency, 
resulting in the disappointing outcome of early clinical trials using imatinib(24-26). In 
2010, Curtin and his colleagues reported that in the rare subsets of acral, mucosal and 
chronic sun damaged (CSD) melanoma, incidence rates of c-KIT genetic aberration are 
36%, 39% and 28% respectively, which are quite high. The most common mutations are 
L576P on exon 11 and K642E on exon 13.While in the subset of melanoma arising from  
skin without chronic sun damage, the mutation rate is zero (27).  There are multiple 
clinical case reports showing that patients with c-KIT mutations respond well to c-KIT 
inhibitors such as dasatinib and imatinib(28-31). More clinical trials determining the 
therapeutic efficacy of c-KIT inhibitors in melanoma are currently ongoing. 
 
Mastocytosis is not a malignant disease per se, but when it progresses to an advanced 
stage, it could evolve into mast cell leukemia. C-KIT mutation drives approximately 95% 
of mastocytosis and D816V mutation is identified in 80% of the patient samples(32-34). 
In  mastocytosis  cell  lines,  studies  have  demonstrated  that  imatinib  can’t  efficiently inhibit 
the activity of c-KIT with D816V mutation, while dasatinib could significantly block its 
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activity and lead to the apoptosis of the cells(35). Therefore, dasatinib might be an 
effective targeted drug for this disease. C-KIT mutations have also been found in germ 
cell tumor and acute myeloid leukemia (core binding factor subtype). The summary of 
the various cancers associated with c-KIT mutations as illustrated below(Table 1) (13, 
36-38). 
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Figure 1 C-KIT structure and signaling schematic diagram.  
 
The extracellular region is encoded by exons 2 through 9, and contains 5 
immunoglobulin-like domains. The Juxtamembrane domain is encoded by exon 11.  
There are 2 intracellular tyrosine kinase domains: the ATP-binding pocket encoded by 
exons 13 and 14, and the kinase activation loop encoded by exon 17. Binding of SCF 
causes the dimerization of c-KIT and autophosphorylation of this receptor, consequently 
triggering the activation of downstream Ras/MEK/MAPK, PI3K/Akt and JAK/STAT 
pathways. 
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Table 1 C-KIT genetic aberrations associated with human malignancies 
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1.3 Dasatinib   
          
Dasatinib, a small molecule tyrosine kinase inhibitor drug, was originally identified as a 
potent Src/Abl inhibitor by researchers at Bristol-Myers Squibb about ten years ago. Due 
to its potent anti-proliferative activity against multiple hematological and solid tumor cell 
lines, it has been approved by FDA for the treatment of  Philadelphia chromosome-
positive acute lymphoblastic leukemia and chronic myelogenous leukemia. The targeted 
kinase spectrum of dasatinib  is quite broad, including Src family members, Bcr/abl, c-
KIT, PDGFR and Ephrin A. The mechanism dasatinib’s action involves its competitively 
binding with the ATP-binding site of the kinase to inhibit the phosphorylation of tyrosine 
involved in the signal transduction. The plasma half-life of dasatinib is only 5-6 hours, 
quite short compared with other tyrosine kinase inhibitors(39).  
 
This drug is currently being tested in clinical trials for treating multiple solid tumors such 
as melanoma, GIST, pancreatic cancer and breast cancer. Even though imatinib is the 
most commonly used c-KIT inhibitor in the clinic, dasatinib has been shown to be a 
potential stronger inhibitor for certain forms of mutant c-KIT. For example, it has been 
shown that L576P, the most common c-KIT mutation in melanoma, is sensitive to 
dasatinib rather than imatinib. One study suggests that the different binding affinities of 
imatinib and dasatinib might be caused by the different structural changes of the mutant 
kinases(31). P815, a tumor cell line with D814Y mutation we used in this model,  is also 
not sensitive to the inhibition of imatinib, but it is sensitive to killing mediated by 
dasatinib. That is why we used dasatinib as the targeted therapy drug in this study(35, 40). 
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1.4 P815 mouse model 
 
P815 is a mastocytoma line induced by a highly carcinogenic compound 
methylcholanthrene(MTA) in a DBA/2 mouse. Tumor antigens, from this immunogenic 
tumor, have been identified and cloned. P1A, the first tumor antigen identified, is a non-
mutated gene normally expressed in the placenta and testis of the DBA/2 mouse. A 
transgenic mouse strain with TCR specific for H-2Ld : P1A complex has been generated 
and named P1CTL mice. People could utilize these transgenic mice to do adoptive T cell 
transfer experiments studying the anti-tumor CTL response in vivo. Another antigen 
identified later on is P1E. Therefore, this model allows people to monitor immune 
responses against two MHC I-restricted epitopes at the same time.  This animal model 
has long been considered as a good tool for analyzing the relationship between tumor and 
anti-tumor T cell immunity. 
 
Studying the combination of targeted therapy and immunotherapy is quite challenging 
due to the low availability of the suitable animal models.  We need an immunogenic 
tumor, whose growth is driven by a single oncogenic event and can be implanted in 
immunocompetent mice. We found that the P815 tumor model fits these criteria. Growth 
of P815 is controlled by a mutant c-KIT receptor (D814Y mutation) and disrupting c-KIT 
signaling could significantly inhibit the proliferation and promote the apoptosis of this 
tumor line. In addition, P815 is a very immunogenic tumor allowing us to study the 
therapeutic effect of  immunotherapy.  
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1.5 Anti-tumor T cell response 
 
The theory of cancer immune surveillance was developed by Burnet and Thomas in 
1950s(41) and it is currently well-accepted that immune system can recognize and 
eliminate malignant cells. Both innate components and adaptive components from the 
immune system play a role in controlling the growth of cancer cells. NK cells, NKT cells 
and macrophages which can directly eliminate the transformed cells are the major players 
of innate anti-tumor immune response(42). T cells are the major effectors of the adaptive 
anti-tumor immunity. The anti-tumor T cell response is a multi-step process. First, tumor 
antigens need to be taken up by dendritic cells, then APCs process the proteins into 
peptides and load them to MHC molecules. Activated dendritic cells then migrate into 
tumor-draining lymph nodes. When naïve T cells with the specific TCR encounter the 
dendritic cells presenting the corresponding peptide, they get activated and undergo 
clonal expansion. During this priming phase, number of the T cell precursors specific to 
an antigen could increase more than 1000 fold and these cells form a pool of effector 
cells. CD8+ effector T cells are normally   considered  as   the   ‘killer   cells’  with   cytolytic  
activity. They migrate into tumor microenvironment following chemokine gradients. 
Once encountering tumor cells, CTLs release vesicles containing perforin and granzymes. 
Perforin is a cytolytic protein forming pores on the cell membrane of the target cells. 
Granzymes are serine proteases which can cleave caspase-3 and activate the downstream 
apoptotic pathway in the target cells. Surface expression of FasL is another mechanism 
CTLs employ to eliminate tumor cells. Engagement of FasL on CTLs and Fas receptor on 
tumor cells activates caspase-8 and triggers the extrinsic apoptotic cascade. Those 
molecules are the major mediators of T cell cytolytic activity. CD4+ effector T cells are 
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generally considered as the T helper cells which coordinate many elements of the 
immune response. They can help activate APCs through CD40-CD40L axis and 
production of cytokines, and they also participate in priming CD8+ T cell as well as 
activating macrophages(43). Recent studies suggest that a subset of CD4+ T cells might 
also possess cytolytic activity and can directly kill tumor cells(44-46). The majority of 
the effector T cells die after the effector phase, leaving a small pool of memory T cells 
which can elicit more rapid response upon secondary antigen stimulation. Because of the 
potent capability of T cells to specifically recognize and eliminate cancer cells, T cells-
based therapies show great promise in developing immune treatment for cancers. 
 
1.6 Immunotherapy of cancer 
 
Cancer immunotherapy is based on the idea of boosting the immune reaction to eradicate 
cancer cells. It has been successfully implemented in the clinical treatment of a number 
of malignancies, such as lymphoma, renal carcinoma and melanoma(47-53). 
Immunotherapy for cancer can be divided into several categories: adoptive cell therapy, 
cytokine based therapy, cancer vaccine and antibodies targeting costimulatory molecules, 
etc (Table 2).  
 
Adoptive cell therapy (ACT) transfers cytolytic lymphocytes which have been stimulated 
or genetically modified ex vivo back into patients. The most effective adoptive cell 
therapy approach for cancer so far is adoptive T cell therapy with tumor infiltrating T 
lymphocytes (TIL) which involves isolation of TILs from   patients’   resected tumor 
masses, ex vivo expansion of isolated TILs to large numbers and re-infusion of those 
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tumor-specific TILs. Clinical responses to ACT in early years were not quite promising, 
but adding preparative lymphodepletion regimen significantly improved the response rate 
of this therapy(54, 55). The potential mechanisms involve increased availability of 
homeostatic cytokines and down-regulation of immune suppressive cells(56). According 
to a recent clinical study conducted at the NCI, the overall response rate for patients 
receiving chemotherapy-based preparative regimen and ACT was 49%, when adding 
12Gy total body irradiation to the standard treatment approach, the overall response rate 
was improved to 72%(57). Compared with other therapeutic regimens, ACT turned out to 
be the most efficient one for late-stage melanoma patients. Multiple clinical trials are 
currently underway to determine the therapeutic efficacy of this immunotherapy approach 
in other types of cancers, including renal carcinoma and ovarian cancer (58). One 
advantage of this approach is enabling people to directly manipulate the transferred T 
cells genetically, which might offer a therapeutic advantage.  Genetic modification can be 
used to re-direct the antigen specificity, enhance the survival and improve the migration 
ability of transferred T cells(59-63).  
 
Cytokine-based therapies have also been successfully implemented in clinical cancer 
treatment. The two most successful examples are IFN-α  and  IL-2.  IFN-α  is  produced  by  
leukocytes and it is one of the first cytokines that has been found to exhibit anti-tumor 
effect.  It does not only induce apoptosis in cancer cells but also stimulates the innate and 
adaptive immune responses against malignant cells. Therefore, IFN- α  has  been  approved 
by the FDA for the treatment of a number of tumors(64).  IL-2 is the first interleukin that 
has been identified and cloned. It is mainly produced by activated T cells and plays a 
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critical role in regulating T cell proliferation, differentiation and survival. In addition to 
its function in  T cells, IL-2 also exerts pleiotropic effect on other subsets of immune 
cells: it could promote the immunoglobulin production by B cells, boost the proliferation 
and activation of NK cells and also affect the function of macrophages and dendritic 
cells(65).  Due to its biological function of expanding and activating cytolytic T cells and 
NK cells, IL-2 has been used in the clinic for cancer treatment for a long time. High dose 
IL-2 therapy could induce response in 15% of the patients and leads to cure in 5%  of the 
patients with late-stage melanoma(66). Therefore, it is considered as one of the first-line 
treatment options for metastatic melanoma. It is also being used for treating renal 
carcinoma and combined with adoptive T cell therapy and cancer vaccines(67). There are 
several other cytokines showing promising results in cancer-related studies, such as GM-
CSF, IL-15 and IL-21. Clinical trials of validating the therapeutic efficacy of those 
cytokines are underway.  
 
Vaccines have been successfully used to induce adaptive immune responses against 
infections in the clinic.  Identification of multiple cancer antigens has paved the way for 
the development of cancer vaccine. The concept of cancer vaccine was proposed long 
time ago and people have conducted extensive studies to develop all sorts of cancer 
vaccine for several decades. Common forms of cancer vaccine include whole cell-based 
vaccine, protein-based vaccine, peptide-based vaccine, DNA-based vaccine, recombinant 
virus vaccine and dendritic cell vaccine. However, the success of vaccines in cancer 
treatment is very limited so far.  Taking melanoma as an example, a study published 2 
years ago showing that gp100 peptide vaccine combined with IL-2 improved the 
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prognosis of  late-stage melanoma patients as compared with IL-2 alone is one of the first 
clinical studies showing that vaccine could provide certain therapeutic effect in late-stage 
cancer patients(68).  For most of the cancer vaccine-related clinical trials, the results 
turned out to be disappointing. Further studies are needed to improve the therapeutic 
efficacy of cancer vaccine. 
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Table 2 Summary of different types of cancer immunotherapy  
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1.7 Costimulatory molecules 
 
T cell activation against tumor antigens is a critical step of an effective anti-tumor 
immune response. After undergoing the positive selection and negative selection in 
thymus, naïve T cells mature and migrate to the peripheral lymph nodes in which they 
might encounter the APC presenting the cognate peptide/ MHC complex. This is the so-
called ‘first-signal’ for the activation of naïve T cells. And the binding between CD28 on 
T cells and CD80/86 on APC is also critical for T cell activation. CD28 activation could 
induce the phosphorylation of  its tyrosine residues, which recruits proteins with SH-2 
domain, such as PI3K and Grb2. Signaling through CD28 enhances the TCR signaling 
and activates the expression of certain anti-apoptosis genes, such as bcl-xl. This provides 
the  ‘second  signal’  for  T  cell  priming.  However, the fate of T cells is finally determined 
by the integration of signals from multiple co-existing molecules in the T cell-APC focal 
synapses. In addition to CD28, costimulatory molecules including 4-1BB, OX40, LAG-3, 
CD27, BTLA, CTLA-4 , PD-1 and several other ones simultaneously play important 
roles in this process. Some of them provide positive signal for T cell activation and some 
of them could negatively interfere with T cell function(Figure 2). When naïve T cells 
encounter antigen presented in the context of proper costimulation, they could undergo 
rapid expansion, differentiation and then become cytotoxic effector cells. However, 
negative signals coming from the costimulatory pathways might result in T cell anergy or 
exhaustion.  Progresses in the understanding of the costimulatory molecules-related 
pathways  has led to the development of several antibodies specific targeting those 
molecules. The most successful examples are anti-CTLA-4 and anti-PD-1.  
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CTLA-4 is an inhibitory checkpoint molecule expressed by T cells right upon T cell 
activation. CTLA-4 competes with CD80/CD86 for receptor binding with CD28. CTLA-
4 ligation inhibits the activation and expansion of  T cells thereby effectively dampens 
the magnitude of an immune response including anti-tumor T cell response(69-71). 
CTLA-4 blockade could  remove  this  ‘brake’  on  T  cells  activation  and   has been shown to 
effectively enhance the anti-tumor immunity in multiple animal models(72, 73). 
Ipilimumab, the antagonistic antibody against CTLA-4, demonstrated superior 
therapeutic effect  when combined with dacarbazine or gp100 vaccine  in melanoma 
clinical trials(74, 75), thus was approved for the treatment of late-stage melanoma in 
2012. Currently, this drug is undergoing clinical trials for treating lung cancer and 
prostate cancer patients.  
 
PD-1 is another key negative regulator expressed by T cells.  Binding of PD-1 ligands 
with PD-1 receptor could render T cells undergo exhaustion and become unresponsive. 
This pathway has been well characterized as negatively controlling the T cell response to 
chronic viral infection and cancer (76, 77).  PD-L1 expression has also been identified in 
various types of tumors and currently is considered one of most important immune 
evasion mechanisms employed by cancer cells(77-81). Increased knowledge about the 
function of PD-1/PD-L1 axis in immune regulation has led to the development of 
antagonistic PD-1 and PD-L1 antibodies. The phase I clinical trials have ensured the 
safety and tolerability of PD-1 and PD-L1 antibodies, and also showed durable 
therapeutic response in some patients. (82-86). Larger clinical trials of treating late-stage 
cancer patients with these antibodies are underway. 
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The initial success of anti-PD-1 and anti-CTLA-4 has raised hope that costimulatory 
antibodies would revolutionize cancer immunotherapy. A number of antibodies against 
other costimulatory molecules have been shown to be effective in preclinical studies, for 
examples, anti-OX40(87, 88), anti-4-1BB(89, 90) and anti-CD40(91, 92).  And studies 
trying to develop new humanized antibodies against those T cell regulatory molecules 
represent an active area of research.  
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Figure 2  Major costimulatory molecules in lymphocytes. 
Costimulatory molecules play an important role in regulating the function of lymphocytes. 
They can be classified into two types: negative and positive costimulatory molecules. 
Important negative costimulatory molecules include programmed cell death protein 1 
(PD-1), B and T lymphocyte attenuator (BTLA) , CD160, cytotoxic T lymphocyte 
antigen 4 (CTL-4), and lymphocyte activation gene 3 (LAG3). Important positive 
costimulatory molecules include CD28, inducible co-stimulator (ICOS), CD137(4-1BB), 
OX40, CD27, glucocorticoid-induced TNFR-related protein (GITR), B cell activation 
factor receptor (BAFFR), transmembrane activator and CAML interactor (TACI), B cell 
maturation antigen (BCMA) and CD40L. Most of those costimulatory molecules belong 
to immunoglobulin(Ig) superfamily or tumor necrosis factor receptor (TNFR) 
superfamily. The ligands for those molecules are mainly expressed by APCs and other 
peripheral cells. Costimulatory pathways are important targets for cancer immunotherapy. 
 
Reprinted by permission from Macmillan Publishers Ltd: Nature Review Drug Discovery 
12(2): 130-46, © 2013 Macmillan Publishers Ltd  
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1.8 Anti-OX40 
 
OX40(CD134) is a costimulatory molecule which belongs to the tumor necrosis family 
receptor  (TNFR) superfamily. It is known to play an important role in the proliferation, 
differentiation, survival and migration of T cells. OX40 is expressed on T cell after its 
activation, with variable dynamics in various conditions. Both TCR signaling and CD28 
ligation have regulatory role on the expression of OX40, and certain cytokines, such as 
IL-2 and TNF, might also prolong or enhance the expression. But generally, the 
expression of OX40 on CD8+ T cells is more transient than CD4+ T cells(93). 
OX40L(CD252) is expressed as a trimer on the cell surface of a number subsets of 
immune cells, such as dendritic  cells, B cells, and endothelial cells(94). OX40 
crosslinking results in OX40 binding with several intracellular adaptors, including 
TRAF2, TRAF3 and TRAF5, which leads to the activation of NF-κB   pathway and 
PI3K/Akt pathway. This prevents T cell apoptosis by enhancing the expression of bcl-2, 
bcl-xl and survivin, and also promotes the division, cytokine production and memory 
response formation through some unknown signaling mechanisms(93).  
 
OX40 and OX40L knockout mice were generated more than a decade ago. OX40 
deficient mice infected with LCMV and influenza virus demonstrated defective CD4+ T 
cell response(95). OX40L deficient mice had reduced dendritic cell mediated-T cell 
priming and contact hypersensitivity response(96).  These early animal studies suggest 
OX40 plays an important role for T cell costimulation. Studies have shown that OX40 
activation could help maintain the survival of effector T cells beyond the initial several 
rounds of cell division after their encounter with antigen. And OX40 agonist can enhance 
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the clonal expansion and formation of memory response for both CD4+ and CD8+ T 
cells in vivo(97, 98). In addition, OX40 ligation on Tregs could effectively block the 
suppressive function of those cells. Studies have found that OX40 stimulation suppresses 
the expression of Foxp3 gene, which is the master regulator of Treg cells, and also 
prevents the induction of Treg cells from CD4+ conventional T cells(99-101). Therefore, 
the advantage of utilizing OX40 ligation to boost T cell response is affecting both the 
effector side and the regulatory side. OX40 has also been shown to be expressed by other 
subsets of immune cells, such as NK, NKT and dendritic cells, and affects function of 
these cells (102-104).  
 
The OX40-OX40L axis has also been shown to be involved in the pathogenesis of 
multiple autoimmune diseases by animal studies. For example, in an induced 
experimental autoimmune encephalomyelitis (EAE) model, OX40L knockout mice 
exhibited much less severe clinical manifestations than the wild type mice(105).  Later on,   
animal experiments demonstrated that expression of OX40L on tumor cells could 
enhance the tumor immunogenicity and mediate the tumor rejection(106), suggesting 
OX40 signaling also plays important role in tumor immunity.  Then, agonistic anti-OX40 
antibody alone was shown to potentiate the anti-tumor immune response in multiple 
tumor models through multiple mechanisms, including promoting effector and memory T 
cell response, suppressing Treg function and enhancing the migration of CTL into tumor 
microenvironment(88, 107, 108). In addition, the combination of anti-OX40 with 
chemotherapy, irradiation therapy and other immunotherapy regimens have also been 
tried and showed promising therapeutic effect(109-112). Those studies have paved the 
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way for translating OX40 ligation therapy into the clinic. A humanized agonistic anti-
OX40 antibody has recently been generated and is being tested in clinical trials. 
 
 1.9 Mechanisms of cancer immunosuppression 
 
A wide variety of mechanisms are employed by cancer cells to evade or subvert an 
immune attack. It is well known that cancer cells can down-regulate their antigen 
presentation machinery to avoid being killed by immune effectors. Mutations in genes 
encoding MHC molecules, TAP and LMPs are commonly seen in cancer cells(113, 114). 
Besides evading the immune attack by impairing the antigen presentation pathway, 
cancer cells could also directly exert inhibitory effect on immune effectors by multiple 
immunosuppression mechanisms, including producing inhibitory cytokines and enzymes, 
recruiting suppressive cells and expressing inhibitory surface molecules(115, 116), which 
are listed below(Table 3). 
 
Cancer cells and the stromal cells in the tumor microenvironment could secrete large 
amounts of inhibitory cytokines such as IL-10(117), TGF-β  (118) and VEGF(119). These 
cytokines can directly inhibit the antigen presentation capability of dendritic cells, the 
proliferation and cytolytic function of T cells and cytokine production by immune 
effectors. Enzymes with immunosuppression properties also profoundly exist in the 
tumor microenvironment. For example, indoleamine 2,3- dioxygenase (IDO)(120), 
arginase(121) and inducible  nitric oxide synthases (iNOS)(116) could catabolize some 
amino acids which are essential for the proliferation and function of T cells. Tumor cells 
can produce chemokines, such as CCL22, CCL2 and CXCL2 to attract regulatory T cell 
 25 
(Treg), myeloid-derived suppressor cell (MDSC) and M2 tumor-associated macrophage 
(TAM) into tumor microenvironment(116, 122, 123). Profound existence of cells with 
immune-inhibitory properties substantially hinders the function of  anti-tumor immune 
cells.  Last but not least, cancer cells can express multiple immune-inhibitory molecules, 
such as PD-L1 and FasL(124-126). Engagement of those molecules with their 
corresponding ligands could lead to T cell exhaustion, anergy or depletion in the tumor 
microenvironment. These mechanisms may act in concert to restrain anti-tumor immunity. 
Therefore, cancer-induced immune suppression is a major obstacle for the success of 
immunotherapy and overcoming it might help eradicate cancer cells successfully.  
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Table 3 Immunosuppressive mechanisms employed by cancer 
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1.10 Rationale for combining targeted therapy and immunotherapy 
 
Advances in the development of multiple targeted therapy agents and immunotherapy 
approaches in the recent years avail a great opportunity for combinatorial therapies. 
There are several rationales for combining these two(127).  
 
Firstly, even though some targeted therapy drugs can induce dramatic tumor shrinkage in 
some patients, the responses are usually of limited durability. And although certain 
targeted therapy drugs are known to be able to induce a high response rate in the subset 
of the patients who have the corresponding mutation, they barely lead to a cure. However, 
immunotherapy is quite different. Although the overall response rates for most of the 
immunotherapy regimens are relatively low, durable and complete responses do happen 
in some patients. In fact, immunotherapy might be the only treatment able to elicit a 
memory response against tumor and provide long-term protection against recurrence. 
Besides, targeted therapy and immunotherapy eradicate cancer cells by completely 
different mechanisms: one is blocking the oncogenic pathway which supports the growth 
of tumor cells, another is boosting the cytotoxic immune cells to eliminate tumor cells. 
The targeted therapy-resistant cells could still be sensitive to immune-mediated killing, 
and tumor cells successfully evade the immune surveillance could still be eliminated by 
blocking their growth signaling. Therefore, those two types of treatments have 
complementary strengths and weaknesses, and combinatorial therapy might provide 
better therapeutic outcomes. 
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Secondly, cancer has been proved to utilize multiple mechanisms to suppress the immune 
system and evade the immune surveillance. These mechanisms are the major contributors 
of cancer immune evasion and cancer-induced immune tolerance. Overcoming  hese 
barriers is one of the keys to the success of immunotherapy. Recent studies have shown 
that certain oncogenic signals could directly up-regulate the immunosuppressive 
mechanisms to advance the tumor growth (128, 129). Therefore, the effectiveness of 
immunotherapy could be enhanced upon the down-regulation of oncogenic signal-
mediated immunosuppression. In addition, some non-specific kinase inhibitors have 
already been shown to exert suppressive effect on immunosuppressive cells. For example, 
sunitinib treatment inhibiting MDSC and Tregs is considered as an additional advantage 
of using this drug to treat renal cancer patients(130). Therefore, if targeted therapy can be 
employed to down-regulate immunosuppressive components, it could be successfully 
integrated into immunotherapy protocol in cancer treatment settings. 
 
Thirdly, the anti-tumor immune response could be induced upon the treatment of a 
number of cytotoxic regimens, because the massive death of cancer cells results in release 
of tumor antigens. In fact, anti-tumor immune response is one of the parameters 
determining the therapeutic outcomes of certain chemotherapies, radiotherapies and 
targeted therapies(131). For example, the polymorphism of  TLR4 gene could serve as an 
independent prognostic factor of  the response to anthracycline and local irradiation in 
breast cancer patients(132). And a correlation of clinical response with CD8 and IFN-γ  
expression levels was also observed in breast cancer patient receiving chemotherapy(133). 
These are all evidences indicating that the anti-tumor immune response might 
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substantially contribute to the therapeutic effect of cytotoxic regimens. In addition, it is 
well-known that some mutant oncogenic proteins function as tumor antigens eliciting 
tumor specific immune response, for example, mutant β-catenin and p53 (134, 135) . 
Besides, deep sequencing analysis of cancer genomes also shows that multiple mutations 
accumulated in tumor cells could potentially be presented by MHC molecules and  
function as target antigens(136). These lines of evidences suggest that tumor debris 
generated in situ after targeted therapy treatment could potentially be a great sources of 
tumor antigen which might initiate strong anti-tumor immune response with appropriate 
boosting strategy.  
 
Therefore, the combinatorial approaches may provide therapeutic synergy and result in 
stronger and more durable clinical response. Studies involving combinatorial therapy are 
currently ongoing. For example, clinical trial testing the therapeutic efficacy of BRAF 
inhibitor vemurafenib and anti-CTLA-4 antibody ipilimumab in melanoma patients is 
being conducted at multiple cancer centers.  
 
However, successful implementation of combinatorial regimen in the clinic requires 
understanding of the interaction of the targeted agent and immune response. In this study, 
we explored the effect of one c-KIT inhibitor dasatinib on anti-tumor T cell response in 
this specific model - P815 mastocytoma mouse model. And we operated under the 
hypothesis that the therapeutic efficacy of the targeted therapy could be enhanced by 
boosting the endogenous anti-tumor immune response with an immune-stimulating 
approach. In doing so, we found that the underlying anti-tumor T cell response is an 
 30 
important   contributory   factor   of   dasatinib’s   therapeutic   effect   in   this   model   and   the  
combination of dasatinib plus anti-OX40 synergizes to induce a potent anti-tumor T cell 
response and provides superior therapeutic effect. 
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Chapter 2.  Dasatinib elicits a strong tumor-specific T cell response 
which contributes substantially to the therapeutic effect of dasatinib 
2.1 T cell–mediated immunity contributes to the anti-tumor effects of dasatinib 
 
It has been shown that dasatinib can suppress the c-KIT kinase activity effectively and 
inhibit the growth of P815 tumor cells in vitro (35, 40).  In our in vitro experiment, we 
also showed that dasatinib could induce apoptosis of P815 cells in a dose-dependent 
manner by Annexin V+7-AAD staining. Dasatinib could induce the apoptosis of P815 
starting at a concentration as low as 10nM (Figure 3A), which indicates that P815 is very 
sensitive to dasatinib. To test whether dasatinib could kill P815 in vivo, we inoculate 
mice subcutaneously with 2×106  tumor cells on their left abdominal walls and  treated the 
tumor-bearing mice with daily gavage of vehicle or different doses of dasatinib (5mg/kg, 
10mg/kg, 50mg/kg and 150mg/kg) on days 8, 9, and 10 following tumor inoculation. We 
found that at the dose of 150mg/kg, dasatinib significantly inhibited the growth of  P815 
and prolonged mouse survival (Figure 3B and 3C). H&E staining right after dasatinib 
treatment revealed extensive vacuolar degeneration in dasatinib-treated tumors, 
morphologic changes consistent with significant tumor cell death (Figure 3D). This result 
suggested that dasatinib could directly induce the cell death of P815 in vivo.  
 
To assess a potential role for T cell-mediated immunity in the therapeutic efficacy of 
dasatinib, we depleted CD4+ and CD8+ T cells in the mice to see how it affected the 
therapeutic effect of dasatinib. We gave the tumor-bearing mice monoclonal antibodies 
against CD4 or CD8, intraperitoneally, starting from day 8 once a week.  Interestingly, 
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both CD4+ T cell-depletion and CD8+ T cell-depletion reduced anti-tumor responses in 
dasatinib-treated mice almost to the same level as in vehicle-treated mice, effectively 
abrogating the survival benefit provided by dasatinib. (Figure 4A and 4B).  This result 
revealed that an underlying immune response contributes substantially to the therapeutic 
anti-tumor effect of dasatinib in this model. 
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Figure 3 In vitro and in vivo anti-tumor effect of dasatinib on P815 mastocytoma. 
For in vitro experiment, P815 cells were treated with DMSO or dasatinib for 24 hours 
then subjected to flow cytometric analysis. For in vivo experiment, DBA/2 mice were 
subcutaneously inoculated with P815 tumor cells on day 0. Tumor-bearing mice were 
treated with vehicle or dasatinib (150 mg/kg) on day 8, 9 and 10 by gavage. (A) Dot plots 
for Annexin V + 7-AAD staining of treated P815 tumor cells. (B) Tumor sizes in mice 
treated with vehicle or dasatinib (*P < 0.05). (C) Kaplan-Meier survival curves of the 
tumor-bearing mice for 2 different groups (*P < 0.05). (D) Representative H&E -stained 
slides of control tumor and dasatinib-treated tumor. 
 
This research was originally published in Blood. Yang Y, Liu C, Peng W, Lizée G, 
Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to 
the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-
OX40. Blood. 2012; 120(23): 4533-43. © the American Society of Hematology 
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 Figure 4 The in vivo anti-tumor effect of dasatinib is dependent on T cells. 
 
Mice  were  injected  i.p.  with  200μg  Rat  IgG  or  CD4  or  CD8  depletion  antibodies starting 
from day 8 once a week. (A) Tumor sizes of CD4+/CD8+ T cell depletion experiment 
(Vehicle+IgG versus Dasatinib +IgG: *P < 0.05). (B) Kaplan-Meier survival curves of 
CD4+/CD8+ T cell depletion experiment (Vehicle+IgG versus Dasatinib +IgG: *P = 
0.05). 
 
This research was originally published in Blood. Yang Y, Liu C, Peng W, Lizée G, 
Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to 
the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-
OX40. Blood. 2012; 120(23): 4533-43. © the American Society of Hematology 
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2.2  Short-term dasatinib treatment can increase levels of circulating tumor antigen-
specific T cells rather than long-term dasatinib treatment 
 
We next sought to determine the effect of dasatinib on the tumor antigen-specific T cell 
response. P815 is an immunogenic tumor which can elicit spontaneous T cell priming 
against tumor antigens. To see how dasatinib affected the anti-tumor T cell immunity, we 
collected the blood of the mice on day 18. Using a P1A-specific tetramer and flow 
cytometry, we found that 3 days of dasatinib treatment significantly increased the tumor 
antigen-specific T cell levels in the peripheral blood of tumor-bearing mice (Figure 5A 
and 4B). Peripheral blood T cells were also examined for antigen-specific IFN-γ  
production using intracellular staining following stimulation with or without P1A, P1E 
peptides for 6 hours. We found that while CD8+ T cells from vehicle-treated mice were 
relatively unresponsive to peptide stimulation, a significant proportion of CD8+ T cells 
from dasatinib-treated mice showed IFN-γ  positivity  (Figure 5C and 5D). IFN-γ  ELISA  
showed results consistent with the intracellular IFN-γ   staining,   which   indicated   that   3  
days of dasatinib treatment significantly augmented the anti-tumor T cell response 
(Figure. 5E). Moreover, CD4+ T cell depletion in vivo significantly compromised the 
enhanced tumor antigen-specific CD8+ T cell response mediated by dasatinib (Figure 5F), 
suggesting that the CD8+ T cell response against P815 is T helper cell-dependent. This 
result also partially explains why in the T cell-depletion experiment, CD4+ T cell-
depletion abrogated the therapeutic benefit provided by dasatinib as well as CD8+ T cell- 
depletion did. 
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However, dasatinib is a multiple tyrosine kinase inhibitor which inhibits the activities of 
c-KIT, EphA, Src family members, Brc/abl , PDGFR and some other tyrosine kinases 
(39). It has been reported that dasatinib inhibits TCR signal transduction, cellular 
proliferation and cytokine production by T cells upon antigen stimulation probably due to 
the inhibitory effect of dasatinib on Src family member Lck (137, 138). So to test 
whether dasatinib has the same effect on the P1A-specific T cells, we first isolated the 
splenocytes from P1CTL transgenic mice, whose TCRs are specific for P1A 
peptide/H2Ld complexes. Then we cultured the CFSE-labeled splenocytes in the presence 
of P1A peptide and different concentrations of dasatinib for 48 hours. Flowcytometry 
showed that dasatinib inhibited the antigen-driven T cell expansion at a dose dependent 
manner (Figure 6A).  We also cocultured pre-activated P1CTL T cells with P815 tumor 
cells or P1A peptide in the presence of different concentrations of dasatinib for 24 hours, 
and the harvested supernatants were subject to IFN-γ  ELISA. ELISA result showed that 
dasatinib significantly inhibited the cytolytic activity of P1A-specific T cells against 
P815, starting at a concentration as low as 10nm(Figure 6B). These results are consistent 
with the previous study showing that dasatinib, like other multiple tyrosine kinase 
inhibitors, directly inhibits T cell proliferation and activity. 
 
Since we observed enhanced T cell response using a 3-day dasatinib regimen, which was 
in contrast with the direct effect of dasatinib on T cell response in vitro, next we 
investigated whether increasing the length of dasatinib treatment is harmful or helpful to 
its therapeutic effect on P815. We found that prolonged dasatinib treatment   didn’t  
provide any enhanced anti-tumor effects or survival benefit compared with short-term 
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dasatinib treatment (Figure 7A and 7B). In fact, P1A tetramer staining showed that long-
term dasatinib treatment actually compromised the positive effect of dasatinib on tumor 
antigen-specific CD8+ T cell priming (Figure 7C), the P1A tetramer+ T cell level in 8-
day treatment group was significantly lower than that in 3-day treatment group.  Our data 
together with results from other groups suggest that antigen-specific T cell responses can 
be impaired with the persistent presence of dasatinib, but this drug is still capable of 
enhancing anti-tumor immune responses if the dosing and schedule are optimized.  
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Figure 5 Effect of dasatinib treatment on tumor antigen-specific T cell response.  
Peripheral blood of the treated mice was collected and subjected to flow cytometric 
analysis on day 18. Cells were also stimulated with P1A and P1E peptides for IFN- γ  
ELISA. (A) Representative dot plots for P1A tetramer staining in the peripheral blood of 
vehicle or dasatinib-treated mice. (B) Percentage of P1A tetramer+ T cells in total CD8+ 
T cells (*P < 0.05). (C) Representative dot plots for intracellular IFN-γ   staining.   (D)  
Percentage of IFN-γ+  T  cells  in  total  CD8+  T  cells  (P1A:  *P  <  0.05,  P1E:  *P  <  0.05).  (E)  
IFN-γ  secretion by peripheral blood T cells in response to the stimulation of P1A or P1E 
peptides detected by ELISA. (P1A: *P < 0.05, P1E: **P < 0.01). (F) P1A tetramer 
staining of CD4+ T cell depletion experiment. 
 
This research was originally published in Blood. Yang Y, Liu C, Peng W, Lizée G, 
Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to 
the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-
OX40. Blood. 2012; 120(23): 4533-43. © the American Society of Hematology 
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Figure 6 Effect of dasatinib on T cell proliferation and cytolytic activity in vitro. 
For proliferation assay, splenocytes from P1CTL transgenic mice were labeled with 
CFSE and cultured with P1A peptide and 0nm, 1nm, 5nm, 10nm, 25nm or 50nm 
dasatinib.  For IFN-γ   release   assay,   P1A-specific T cells were cultured alone or with 
P815 cells or with P1A peptide for 24 hours. (A) Histograms of the CFSE (FITC channel) 
gated on CD8+ cells 48 hours after labeling. (B) IFN-γ  secretion  by  P1A-specific T cells 
detected by ELISA. 
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Figure 7 Therapeutic effects of short-term dasatinib treatment versus long-term 
dasatinib treatment.  
(A) Tumor sizes in mice treated with vehicle or 3-day dasatinib or 8-day dasatinib. (B) 
Kaplan-Meier survival curves of mice treated with vehicle or 3-day dasatinib or 8-day 
dasatinib. (C) Percentage of P1A tetramer+ T cells in total CD8+ T cells for these 3 
groups (Vehicle versus 3-day dasatinib: **P < 0.01, 3-day dasatinib versus 8-day 
dasatinib: *P < 0.05). 
 
This research was originally published in Blood. Yang Y, Liu C, Peng W, Lizée G, 
Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to 
the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-
OX40. Blood. 2012; 120(23): 4533-43. © the American Society of Hematology 
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2.3 Dasatinib down-regulates certain immunosuppressive components in P815 tumor-
bearing  mice,  which  mediates  dasatinib’s  effect  of  enhancing  anti-tumor T cell 
response. 
 
2.3.1  APCs from dasatinib-treated  mice  don’t present more tumor antigen than the 
APCs from control group. 
 
One of the most possible mechanisms to explain why there are higher levels of P1A- 
specific T cells in dasatinib treated-mice is: drug-induced apoptosis of tumor cells could 
generate tumor debris which might be taken up by APCs, and the tumor antigens 
presented by the APCs might mediate the priming of tumor-specific T cells. To test 
whether this hypothesis is valid here, we set out to assess the amount of tumor antigen 
P1A presented by the APCs in the tumor-draining lymph nodes with or without dasatinib 
treatment. After we treated the mice with vehicle or dasatinib, we isolated the tumor-
draining lymph nodes and sort out CD11b+ CD11c+ dendritic cells and coculture them 
with pre-activated P1A-specific T cells overnight in the presence of Golgi-Plug, after 
which IFN-γ   intracellular   staining  was  done   to   assess   the   reactivation  of   those  T  cells.  
We found that levels of antigen presented by the dendritic cells between these two groups 
were not significantly different. The IFN-γ  production  of   the  P1A-specific T cells after 
stimulation was comparable in these two groups, which indicated that there was not more 
tumor antigen presented by APCs to T cells after dasatinib treatment (Figure 8).  
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Figure 8 IFN-γ  staining  of  P1A-specific T cells stimulated with dendritic cells from 
lymph nodes of the vehicle or dasatinib-treated mice. 
Splenocytes from P1CTL transgenic mice were collected and culture with IL-2 and anti-
CD3 for 7 days. CD11b+CD11c+ cells from the lymph nodes of the treated mice were 
sorted out by FACS. P1A-specific T cells and dendritic cells were co-cultured for 8 hours 
and then subjected to flow cytometric analysis. Dot plots show the IFN-γ   intracellular  
staining of P1A-specific T cells. 
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2.3.2 Dasatinib treatment can decrease the proportion of regulatory T cells and 
enhance vaccine-mediated T cell priming, but doesn’t  decrease  the  proportion  of  
myeloid-derived suppressor cells (MDSC) 
 
Dasatinib has been reported to suppress the proliferation and function of Treg cells in 
vitro(139), but the in vivo effect of dasatinib treatment on murine Treg cells has not been 
reported. Flow cytometric analysis showed that dasatinib alone significantly decreased 
the percentage of Foxp3+CD25+ Treg cells in total CD4+ T cells in the peripheral blood 
of tumor-bearing mice (Figure 9A and 9B). The ratio of Tregs to CD8+ effector T cells 
was also markedly decreased by dasatinib (Figure 9C). We also examined the Treg levels 
within the tumor microenvironment immediately following treatment and found a similar 
decrease in dasatinib group (Figure 9D). However, this decrease was transient, as Treg 
cell numbers went back to normal 3 days after drug withdrawal (9E).  
 
Because fast-growing tumors are usually accompanied by expansion of Treg cells, to 
identify whether this dasatinib-induced decrease in the Treg proportion was due to 
decreased tumor volume or a direct inhibitory effect of dasatinib on Treg, we treated  
tumor-free mice with dasatinib for 3 days. We observed a similar decrease in Treg cells 
in the dasatinib-treated tumor-free mice, suggesting that dasatinib has a direct inhibitory 
effect on Treg cell levels (Figure 10A).  Since the drop in Tregs was significant, we next 
investigated whether the short Treg-depleted window caused by dasatinib can render T 
cells more amenable to vaccine-induced antigen-specific expansion in a tumor-free 
system. We i.v. injected the mice with splenocytes from P1CTL transgenic mice. After 3 
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days of dasatinib treatment, P1A peptide-pulsed dendritic cells were transferred into the 
recipients. Flow cytometric analysis of peripheral blood on day 7 after vaccination 
showed that magnitude of P1A-specific T cell expansion was significantly higher in 
dasatinib-treated group(Figure 10B and 10C). Therefore, this result supports the idea that 
dasatinib preferentially decreases Tregs in vivo and makes the host immune environment 
more favorable for antigen-driven effector T cell proliferation.  
 
We also checked myeloid-derived suppressor cell levels in those mice. Peripheral blood 
samples of the tumor-bearing mice after 3-day dasatinib treatment were collected and 
subjected to flow cytometric analysis. In mice, cells expressing Gr1 and CD11b are 
considered as MDSCs(140). To further distinguish between subset of MDSCs, we also 
stained for another marker Ly6C. Ly6Chigh population is monocytic MDSC and Ly6Clow 
population is granulocytic MDSC(141, 142). We found that dasatinib   treatment   didn’t  
significantly change the proportion of MDSCs in leukocyte population. And the 
percentages of granulocytic and monocytic MDSCs were not affected by drug treatment 
either.  We also did complete blood count test (CBC) for peripheral blood samples, and 
data showed that 3-day dasatinib   treatment   didn’t   significantly   change the leukocyte 
counts in treated mice(Figure 11). It has been shown that other c-KIT inhibitors such as 
imatinib and sunitinib can down-regulate MDSC level in animal models and cancer 
patients(130, 143).  However,  in  our  study,  we  didn’t  observe  significant  drop  of  MSDCs 
after dasatinib treatment. Therefore, it is unlikely that the augmented T cell response in 
dasatinib-treated mice is attributed to the change in the MDSC population.  
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Figure 9 Effect of 3-day dasatinib treatment on levels of regulatory T cells. 
Peripheral blood of the treated mice was collected and subjected to flow cytometric 
analysis on day11 and day14. (A) Representative dot plots for Treg staining in the 
peripheral blood of tumor-bearing mice on day11. (B) Percentage of Treg cells in CD4+ 
T cells in the peripheral blood of tumor-bearing mice on day11(***P < 0.001). (C) 
Treg/CD8+ T cell ratio in the peripheral blood of tumor-bearing mice on day11(***P < 
0.001).  (D) Percentage of Treg cells in CD4+ T cells in tumors on day11 (*P < 0.05). (E) 
Percentage of Treg cells in CD4+ T cells in the peripheral blood of tumor-bearing mice 
on day14. 
 
This research was originally published in Blood. Yang Y, Liu C, Peng W, Lizée G, 
Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to 
the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-
OX40. Blood. 2012; 120(23): 4533-43. © the American Society of Hematology 
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Figure 10 Effect of 3-day dasatinib pre-treatment on vaccine-mediated T cell 
priming. 
(A) Percentage of Treg cells in CD4+ T cells in the peripheral blood of tumor-free mice 
(**P < 0.01) after 3-day vehicle or dasatinib treatment (B) Treg/CD8+ T cell ratio in the 
peripheral blood of tumor-free mice after 3-day vehicle or dasatinib treatment (*P < 0.05) 
(C) Representative dot plots for P1A tetramer staining in the peripheral blood on day 7 
after vaccination. (D) Percentage of P1A tetramer+ T cells in total CD8+ T cells on day 7 
after vaccination( ***P < 0.001).   
 
This research was originally published in Blood. Yang Y, Liu C, Peng W, Lizée G, 
Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to 
the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-
OX40. Blood. 2012; 120(23): 4533-43. © the American Society of Hematology 
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Figure 11 Effect of 3-day dasatinib treatment on levels of MDSC. 
Peripheral blood of the treated mice was collected and subjected to flow cytometric 
analysis and CBC test on day 11. (A) Representative dot plots for MDSC staining in the 
peripheral blood of tumor-bearing mice. (B) Percentage of MDSC in leukocytes in the 
peripheral blood of tumor-bearing mice. (C) Percentage of monocytic MDSC in 
leukocytes in the peripheral blood of tumor-bearing mice.  (D) Percentage of granulocytic 
MDSC in leukocytes in the peripheral blood of tumor-bearing mice. (E) Leukocyte count 
in the peripheral blood of tumor-bearing mice.  
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2.3.3 Down-regulation of IL-10 production by tumor cells is another factor 
contributing  to  dasatinib’s  effect  of  enhancing  anti-tumor T cell response. 
 
Profound immunosuppression is commonly found within the tumor microenvironments 
of various types of cancer. And it is one of the most critical mechanisms of tumor 
immune evasion. Therefore, it is possible that there are some immune modulatory 
components existing in the tumor microenvironment have contributed to the enhanced 
anti-tumor T cell response after dasatinib treatment. To investigate whether any changes 
in immunomodulatory gene expression occurred in the tumor microenvironment after 3 
day dasatinib treatment, tumor samples were harvested and analyzed for changes in 
transcription profiles using gene expression microarray. In P815 tumor microenvironment 
with or without dasatinib treatment, expression levels of certain immunomodulatory 
genes were quite different. One of the most significant changes observed among the 
immune-related genes was that of IL-10 transcription. Dasatinib treatment significantly 
down-regulated the level of IL-10 mRNA in the tumor microenvironment (Figure 12). 
Considering that IL-10 is a well-known immunosuppressive cytokine, this might suggest 
that IL-10 down-regulation is one of the mechanisms contributing to the enhanced anti-
tumor immune response in dasatinib-treated mice. Next, we wanted to determine the 
protein levels of  immunomodulators in tumor microenvironment by Luminex analysis. 
The results also showed a significant decrease in IL-10 production after dasatinib 
treatment (Figure 13). 
 
To determine whether the down regulation of IL-10 in the tumor microenvironment was 
relevant for the improved anti-tumor T cell response induced by dasatinib, we gave mice 
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anti-IL-10 blocking antibody after starting dasatinib treatment and monitored the tumor 
growth and anti-tumor T cell response. We found that IL-10 blockade significantly 
suppressed the tumor growth and improved the survival of the mice (Figure   14A   and  
14B). Tetramer staining showed that compared with control group, blocking IL-10 also 
helped T cell priming (Figure 14C). This result suggested that the down-regulation of this 
tumor-derived immunosuppressive cytokine after targeted therapy treatment is another 
factor contributing to the anti-tumor T cell response induced by dasatinib. 
 
The notion that constitutive activation of oncogenic pathways could up-regulate a number 
of immunosuppressive mechanisms has been supported by several recent studies (129, 
144). For example, one study has shown that c-KIT signaling regulates the expression 
levels of IDO, an enzyme which can convert tryptophan into immunosuppressive 
metabolites in GIST. Furthermore, imatinib treatment suppresses the activation of the c-
KIT pathway, thereby inhibiting the production of IDO by tumor cells and reactivating 
the T cell-mediated anti-tumor immune response (128). This study revealed a link 
between c-KIT and an immunosuppressive molecule. Therefore, it is possible that a link 
between c-KIT signaling and other immunoregulatory cytokines, such as IL-10, also 
exists.  Besides, ERK and p38 activation have been shown to be involved in IL-10 
expression (145, 146), and both are downstream molecules in the c-KIT activation 
pathway. Therefore, we next set out to determine the effect of c-KIT signaling on the 
transcription of immune-related molecules, especially IL-10.  We  knocked  down  c-KIT  by  
siRNA  (Figure  15A  and  15B)  and  used  microarray  analysis  to  assess  how  the  expression  
of  immunomodulatory  gene  products  was  affected.  We  also  treated  P815  tumor  cells  with  
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DMSO   or   25nm   dasatinib   in   vitro   for   24   hours   and   analyzed   those   samples   by  
microarray.  We  found  that  certain  immune-related  gene  expression  levels  were  altered  by  
c-KIT   knockdown:   for   example,   IL-4,   IL-6   and   IL-13;;   however,   these   changes   were  
moderate  and  not  significant.  In  contrast  to  what  we  found  in  the  microarray  analysis  of  
in  vivo  dasatinib   treatment,   IL-10  mRNA  levels   in  c-KIT  knockdown  P815   tumor  cells  
and  in  vitro  dasatinib-treated  P815  tumor  cells  were  higher  than  the  control  cells  (Figure  
16),   indicating   that   the   decreased   level   of   IL-10   in   the   tumor   microenvironment   after  
targeted   drug   treatment   is   not   dictated   by   the   ‘   tune-down’   of   the   oncogenic   c-KIT  
signaling  in  this  tumor  model,  but  may  have  been  caused  by  the  decreased viability of IL-
10-producing tumor cells directly. Still, our study suggests that the decreased  production  
of   immunosuppressive   cytokines   caused   by   targeted   agent-mediated   tumor   cell   death  
might augment T cell priming, contributing to the anti-tumor immune response and 
preventing the tumor immune escape. 
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Figure 12 Gene expression profiles of P815 tumors treated with vehicle or dasatinib.  
24 hours after vehicle or dasatinib treatment, P815 tumors were harvested and subjected 
to microarray analysis. 20 most differentially expressed immune-related genes were 
selected based on the fold changes of the means of the 2 samples in each group. Heatmap 
shows the color-coded expression levels of the selected immune-related genes for tumor 
samples treated with vehicle or dasatinib.  
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Figure 13 Cytokine profiles in the tumor microenvironment of P815 tumors treated 
with vehicle or dasatinib.  
After 3-day vehicle or dasatinib treatment, tumors were harvested and subjected to 
Luminex assay. Bar graphs show cytokine profiles in the lysates of vehicle or dasatinib-
treated P815 tumors (For IL-10, Vehicle versus Dasatinib: *P< 0.05). 
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Figure 14 Effect of IL-10 blockade on tumor growth, survival and T cell response. 
Mice   were   injected   i.p.   with   200μg   control   IgG   antibody   or   IL-10 blocking antibody 
starting from day 8 once a week and also treated with vehicle or dasatinib on day 8, 9 and 
10. Peripheral blood of the treated mice was collected and subjected to flow cytometric 
analysis on day 18. (A)Tumor sizes for 3 different groups (Vehicle+IgG versus 
Vehicle+anti-IL-10 : *P < 0.05). (B) Kaplan-Meier survival curves for 3 different groups 
(Vehicle+IgG versus Vehicle+anti-IL-10: *P < 0.05). (C) Percentage of P1A tetramer+ T 
cells in total CD8+ T cells (Vehicle+IgG versus Vehicle+anti-IL-10 : *P < 0.05). 
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Figure 15  SiRNA-mediated c-KIT knockdown in P815 cells 
P815 cells were transfected with non-targeting siRNA or siRNA against c-KIT. 24 hours 
after transfection, P815 cells were harvested and subjected to realtime PCR and flow 
cytometric analysis. (A)Taqman realtime PCR shows c-KIT mRNA levels in P815 cells 
transfected with non-targeting siRNA (NT RNA) or siRNA against c-KIT or no 
siRNA.(*P < 0.5). (B) Histogram shows the c-KIT protein levels in P815 cells 
transfected with non-targeting siRNA (NT RNA) or siRNA against c-KIT or no siRNA.  
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Figure 16 Gene expression profiles of P815 tumor cells.  
P815 cells were transfected wit c-KIT siRNA pool or non-targeting pool. 24 hours or 36 
hours after transfection, P815 cells were harvested and subjected to microarray analysis. 
P815 cells were also treated with DMSO or dasatinib in culture for 24 hours and then 
subjected to microarray analysis. Heatmap shows the color-coded expression levels of the 
selected immune-related genes for P815 cells.  
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Chapter 3. The therapeutic effect of dasatinib on P815 and underlying 
anti-tumor responses are potentiated by anti-OX40 
3.1 Addition of anti-OX40 antibody improves the anti-tumor efficacy of dasatinib 
treatment. 
 
Since we found that the anti-tumor effects of dasatinib were largely dependent on CD8+ 
T cells, we hypothesized that providing further co-stimulation of these T cells with 
agonistic antibodies could further boost the therapeutic response. Since anti-CTLA-4 and 
anti-PD-1 are costimulatory antibodies already available in the clinic, we decided to try 
these 2 antibodies. Anti-OX40 is a highly promising agonistic antibody currently 
undergoing preclinical and clinical investigation, so we also include this antibody in our 
initial screening. We treated 8-day tumor-bearing mice with dasatinib or vehicle for 3 
days and then administered 2 doses of these 3 antibodies on days 10 and 13 (Figure 17). 
As indicated by the survival curve of the tumor-bearing mice, combination of dasatinib 
and anti-OX40 gave the best anti-tumor effect. Survival curve indicated that neither the 
combination of dasatinib with anti-CTLA-4 nor combination of dasatinib with anti-PD-1 
provided synergistic therapeutic effect. While combining dasatinib with anti-OX40 led to 
significantly enhanced tumor regression and complete cure in 75% of the mice (Figure 
18A-C). The therapeutic effect of the combination treatment was striking considering the 
large tumor burden (60mm2-80mm2) at the time of treatment. To determine whether T 
cells are the major mediator of this therapeutic effect, mice were injected with CD4 or 
CD8 depletion antibodies starting from day 8 once a week. Depletion of CD8+ , and to a 
lesser extent CD4+, T cells abolished the therapeutic effect of dasatinib combined with 
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anti-OX40 (Figure 18D), supporting the notion that T cells are the major immune effector 
cells responsible for the therapeutic effect of this combination regimen. 
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Figure 17 Therapeutic effect of combining dasatinib with anti-OX40/anti-PD-1/anti-
CTLA-4 antibody.  
Mice received daily gavage of vehicle or dasatinib (150mg/kg) on day 8-10 and i.p. 
injection of IgG control antibody or 200µg anti-OX40  or 200µg anti-PD-1 or 100ug anti-
CTLA-4 on day 10 and 13. (A) Schema of treatment. (B) Kaplan-Meier survival curves 
of the tumor-bearing mice for 8 different groups. 
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Figure 18 Therapeutic effect of combining dasatinib and anti-OX40.  
(A)Tumor sizes for 4 different groups (Vehicle+IgG versus Dasatinib+anti-OX40: ***P 
< 0.001, Dasatinib+IgG versus Dasatinib+anti-OX40: **P < 0.01, Vehicle+anti-OX40 
versus Dasatinib+anti-OX40: *P < 0.05). (B) Kaplan-Meier survival curves of the tumor-
bearing mice for 3 different groups (Vehicle+IgG versus Dasatinib+anti-OX40: ***P < 
0.001, Dasatinib+IgG versus Dasatinib+anti-OX40: **P < 0.01, Vehicle+anti-OX40 
versus Dasatinib+anti-OX40: *P < 0.05). (C) Plots represent the tumor size of individual 
mice for each group. (D) Kaplan-Meier survival curves of CD4+/CD8+ T cell depletion 
experiment.  
 
This research was originally published in Blood. Yang Y, Liu C, Peng W, Lizée G, 
Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to 
the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-
OX40. Blood. 2012; 120(23): 4533-43. © the American Society of Hematology 
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3.2 The combination regimen increases the infiltration of tumor-specific CD8+ T cells 
in the tumor microenvironment.  
 
Although it has been reported that OX40 agonist therapy can enhance the expansion and 
survival of CTL(111), we found that addition of anti-OX40 to the dasatinib regimen did 
not further enhance or prolong the tumor antigen-specific T cell response in our tumor 
model: the percentages of P1A tetramer+ CD8+ T cells were similar between the 
dasatinib-treated group and the combination-treated group (Figure 19A-D). Considering 
that the combination treatment yielded a much better therapeutic effect than dasatinib 
alone, we next sought to assess the effect of this combination regimen on T cell 
infiltration of the tumor site. Thus, tumor infiltrating lymphocytes were isolated from 
P815 tumors on day 16 and subjected to flow cytometric analysis. We found that anti-
OX40 alone increased the overall infiltration of CD8+ effector T cells, as previously 
reported. And the combination of dasatinib and anti-OX40 led to enhanced infiltration of 
P1A-specific T cells into the tumors, to levels greater than that observed with either anti-
OX40 or dasatinib alone (Figure. 20A and 20B). IFN- γ  staining  of  TILs  also  showed  that  
mice receiving the combination demonstrated the highest levels of IFN-γ production in 
response to P1A antigen stimulation (Figure 20C).  This result is consistent with a model 
whereby dasatinib enhances the level of circulating tumor-specific T cells and anti-OX40 
helps those CTL migrate into tumor site. 
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Figure 19 Effect of dasatinib and anti-OX40 treatment on the level of the P1A-
specific T cells in the peripheral blood.  
Peripheral blood of the treated mice was collected and subjected to flow cytometric 
analysis on (A) day 14, (B) day 18, (C) day 21 and (D) day 26. Graphs show the 
percentages of P1A tetramer+ cells in CD8+ T cells. 
 
 
This research was originally published in Blood. Yang Y, Liu C, Peng W, Lizée G, 
Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to 
the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-
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Figure 20 Influence of dasatinib and anti-OX40 treatment on the tumor infiltrating 
lymphocytes.  
(A) Total number of CD8+ T cells and the ratio of CD8+ T cells number/tumor weight 
(For CD8+ T cells total number, Vehicle+IgG versus Vehicle+anti-OX40: ***P < 0.001, 
Dasatinib+IgG versus Dasatinib+anti-OX40: *P < 0.05, Vehicle+IgG versus 
Dasatinib+anti-OX40: *P < 0.05; For CD8+ T cells number/gram, Vehicle+IgG versus 
Vehicle+anti-OX40: ***P < 0.001, Dasatinib+IgG versus Dasatinib+anti-OX40: *P < 
0.05, Vehicle+IgG versus Dasatinib+anti-OX40: **P < 0.01). (B) Total number of P1A 
tetramer+ CD8+T cells and the ratio of P1A tetramer+ CD8+ T cells number/ tumor 
weight (For P1A tetramer+ T cells total number, Vehicle+anti-OX40 versus 
Dasatinib+anti-OX40: *P < 0.05, Dasatinib+IgG versus Dasatinib+anti-OX40: **P < 
0.01, Vehicle+IgG versus Dasatinib+anti-OX40: **P < 0.01; For P1A tetramer+ T cells 
number/gram, Vehicle+anti-OX40 versus Dasatinib+anti-OX40: *P < 0.05, 
Dasatinib+IgG versus Dasatinib+anti-OX40: *P = 0.05, Vehicle+IgG versus 
Dasatinib+anti-OX40: *P < 0.05). (C) Total number of IFN-γ+  CD8+T  cells  and  the  ratio  
of IFN-γ+   CD8+T   cells   number/tumor   weight   (For   IFN-γ+   T   cells   total number, 
Vehicle+anti-OX40 versus Dasatinib+anti-OX40: ***P < 0.001, Dasatinib+IgG versus 
Dasatinib+anti-OX40: ***P < 0.001, Vehicle+IgG versus Dasatinib+anti-OX40: ***P < 
0.001; For IFN-γ+   T   cells   number/gram,   Vehicle+anti-OX40 versus Dasatinib+anti-
OX40: *P < 0.05, Dasatinib+IgG versus Dasatinib+anti-OX40: *P = 0.05, Vehicle+IgG 
versus Dasatinib+anti-OX40: *P <0.05 ) 
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3.3 The combination of dasatinib and anti-OX40 leads to up-regulation of IFN-γ  and  
IFN-γ induced chemokines in the tumor microenvironment.  
 
Since the repertoire of chemokines at the tumor site is an important determinant for 
whether sufficient CTL can be recruited to mediate a successful immune response, we 
next sought to determine whether the combination regimen impacted the chemokine 
profile within the tumor microenvironment. Quantitative RT-PCR was used to assess the 
transcript expression of a panel of chemokines. The results showed that the combination 
of dasatinib and anti-OX40 significantly increased the expression of the IFN-γ   induced  
chemokines CXCL9, 10 and 11 in the tumor microenvironment compared with other 
groups (Figure 21). The high levels of CXCL 9, 10 and 11 in the combination treatment 
group correlated with an increased proportion of tumor-infiltrating antigen-specific T 
cells, and improved therapeutic efficacy. This result suggests that induction of IFN-γ  
associated chemokines may induce the migration of effector T cells into tumors to induce 
strong anti-tumor immunity following dasatinib plus anti-OX40 treatment. 
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Figure 21 Levels of CXCL9, 10 and 11 in tumors from 4 different groups.  
Tumors were harvested on day 16 after tumor inoculation. Real-time PCR was performed 
to detect the chemokine levels in the tumor microenvironment. GAPDH was used as the 
normalization reference gene. Graph shows the normalized fold expression of CXCL 9, 
10 and 11 (CXCL9: ***P <0.001, CXCL10: *P < 0.05, CXCL11: *P < 0.05). 
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3.4 Combining dasatinib with anti-OX40  leads  to  a  ‘dual  inhibition’  of  Treg  and 
increases the CD8+ T cell / Treg ratio in the tumor microenvironment.  
 
Next, we investigated the effect of this combination on Treg levels and function. Flow 
cytometric analysis of peripheral blood on day 11 showed that the addition of anti-OX40 
to  dasatinib  didn’t  further down-regulate Treg levels, but Treg levels in the combination 
group remained much lower than that in the control group(Figure 22A and 22B). Since 
both dasatinib and anti-OX40 have been shown to exert inhibitory effects on Treg 
function(100, 101, 139), we performed a Treg suppression assay to characterize Treg 
function in these mice. CD4+CD25high cells were isolated from the spleens of drug-
treated mice and cultured with CFSE-labeled T effector cells, and the proliferation of the 
T effector cells was analyzed by flow cytometry 3 days later. We found that the 
combination of dasatinib and anti-OX40 resulted in Tregs with less suppressive function 
compared with the other three groups, suggesting that inhibition of Treg function 
provides an additional benefit of combining these two agents together(Figure 22C). We 
also examined the effect of this combination on Treg levels in the tumor 
microenvironment on day 16. The numbers of the Treg cells infiltrating tumors were 
highly variable, with no statistically significant differences between the groups(Figure 
22D). However, we did find that the combination regimen significantly increased the 
ratio of CD8+ effector T cells to Treg cells within the tumor microenvironment (Figure 
22E), which is known to be favorable for T cell-mediated tumor rejection. 
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Figure 22 Effect of dasatinib and anti-OX40 treatment on the level and function of 
regulatory T cells.  
(A) Percentage of Treg cells in CD4+ T cells in the peripheral blood on day 11 
(Vehicle+IgG versus Dasatinib +IgG: ***P <0.001, Vehicle+anti-OX40 versus 
Dasatinib+anti-OX40: **P < 0.01, Vehicle+IgG versus Dasatinib+anti-OX40: *P <0.05). 
(B) Treg/CD8+ T cell ratio in the peripheral blood on day11 (Vehicle+IgG versus 
Dasatinib +IgG: ***P <0.001, Vehicle+anti-OX40 versus Dasatinib+anti-OX40: **P < 
0.01, Vehicle+IgG versus Dasatinib+anti-OX40: *P <0.05) (C) Influence of dasatinib and 
anti-OX40 on the function of Tregs isolated from 4 different groups (Vehicle+IgG versus 
Dasatinib+IgG: *P < 0.05 Vehicle+IgG versus Vehicle+anti-OX40: *P < 0.05, 
Dasatinib+IgG versus Dasatinib+anti-OX40: **P < 0.01, Vehicle+anti-OX40 versus 
Dasatinib+anti-OX40: *P < 0.05, Vehicle+IgG versus Dasatinib+anti-OX40: ***P < 
0.001 ). (D) Total number of Tregs in tumor infiltrating lymphocytes on day 16. (E) Ratio 
of CD8+ T cell/Treg in tumor infiltrating lymphocytes on day 16 (Vehicle+anti-OX40 
versus Dasatinib+anti-OX40: **P < 0.01, Dasatinib+IgG versus Dasatinib+anti-OX40: 
*P <0.05, Vehicle+IgG versus Dasatinib+anti-OX40: ***P < 0.001). 
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3.5 The therapeutic effect of 3-day dasatinib combined with anti-OX40 is better than 8-
day dasatinib combined with anti-OX40 
 
Although 3-day dasatinib and 8-day dasatinib achieved similar overall therapeutic effect 
in P815 tumor-bearing mice, we showed these 2 regimens were quite different in terms of 
inducing anti-tumor immunity. 3-day dasatinib treatment enhanced the tumor-specific T 
cell priming while 8-day dasatinib treatment suppressed this T cell response. Next, we 
explored when combined with anti-OX40, which regimen could achieve better 
therapeutic effect. The survival curve clearly indicated that the combination of  3-day 
dasatinib with anti-OX40 provided better therapeutic effect than the combination of 8-
day dasatinib with anti-OX40(Figure 23A and 23B). This result is consistent with our 
expectation: with short-term treatment, tumor antigen-specific T cells prime and largely 
exist in the circulation which later on are attracted into tumor microenvironment with the 
help of anti-OX40; however, in mice treated with long-term dasatinib, the level of tumor-
specific T cells in the circulation is comparatively low, therefore, CTLs attracted into 
tumor microenvironment are not many. 
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Figure 23 Therapeutic effects of short-term dasatinib combined with anti-OX40 
treatment versus long-term dasatinib treatment combined with anti-OX40.  
(A) Tumor sizes in mice for 3 different groups. (B) Kaplan-Meier survival curves of mice 
for 3 different groups. (3-day dasatinib + anti-OX40 versus 8-day dasatinib + anti-OX40: 
*P = 0.05). 
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Chapter 4. Discussion and future directions 
 
4.1 Summary and discussion 
 
Starting with the observation that the anti-tumor effect of dasatinib in P815 mastocytoma 
model largely relied on the presence of T cells, we subsequently found that short-term 
dasatinib treatment could induce a potent tumor specific-T cell response. We next 
identified the mechanism by which dasatinib promoted the priming of  tumor-specific T 
cells, which was through the attenuation of certain immunosuppressive factors, including 
Treg cells and IL-10. The addition of anti-OX40 further potentiated this anti-tumor 
immune response by increasing CTL migration into the tumor microenvironment. The 
combination of dasatinib and anti-OX40 turned out to be a potent therapy which resulted 
in tumor clearance in most of the treated mice. This study demonstrates a strategy by 
which targeted drug and immune-based therapy can be combined to achieve better anti-
tumor responses and provides experimental evidence to support moving this 
combinatorial regimen into clinical trials. 
 
The therapeutic effect of molecular targeted drugs has long been believed to be primarily 
due to direct tumoricidal effects from oncogenic pathway blockade. However, in our 
study we show that, in addition to the direct cytotoxic effects of targeted therapy drugs, 
an underlying immune response also contributed significantly to the tumor eradication in 
our model. We observed that 3-day dasatinib treatment triggered a potent anti-tumor T 
cell response, and that depletion of CD4+ or CD8+ T cells resulted in a significant 
blunting of the anti-tumor effect of dasatinib. This result is consistent with the recent 
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emerging  notion   that  preserving  patients’   immune  function  during   the  administration  of  
cancer therapy regimens might help achieving optimal therapeutic effects.  
 
A major area of concern relates to deleterious off-target effects of small molecule 
tyrosine kinase inhibitors, including the potentially suppressive effect of these drugs on 
immune cells. In particular, dasatinib has been shown to inhibit antigen-dependent T cell 
proliferation both in vitro and in vivo (137, 138, 147), and this negative effect has been 
attributed   to  dasatinib’s   inhibitory  effect  on   the  activity  of   the Src family member Lck, 
which plays a critical role in the TCR signal transduction pathway (138).  Other studies 
have shown that dasatinib treatment in vitro decreased ERK and Akt activity in T cells 
upon TCR stimulation (137). However, evidence from clinical practice suggests that this 
drug may not be entirely immunosuppressive. A clinical study showed that in CML and 
Ph+ ALL patients treated with dasatinib, a significant proportion of the patients 
developed marked lymphocytosis which was attributed to the clonal expansion of NK 
cells and cytotoxic T cells(148).  In addition, one of the most common side effects of 
dasatinib is pleural effusion, a potentially immune-mediated reaction wherein high 
numbers of lymphocytes are found in the pleural fluid of patients (149). The apparent 
discrepancy between the clinical experience and studies in animal models may be due to 
differences in the treatment schedule and dose. Our study addresses this paradoxical issue. 
We found that 3 day-dasatinib treatment stimulated a potent tumor antigen-specific T cell 
response; however, 8 day-dasatinib treatment suppressed the development of the T cell 
response. When combined with an immunomodulatory antibody anti-OX40, the 
therapeutic effect of long-term dasatinib treatment was even worse than short-term 
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treatment. This suggested that prolonged inhibition of T cells caused by persistent 
administration of the tyrosine kinase inhibitor might be undesirable, considering that 
preserving patients’ anti-tumor immunity is beneficial. Under normal circumstances, T 
cell response peaks around day 6-8 days after antigen encounter. When we gave mice 
dasatinib for 3 days, we created a short-term  window  of  ‘low  Treg/  T  effector  ratio’  and  
‘low  IL-10  level’,  which  provided  T  cells  with  a  better  opportunity  to  mount  an  effective  
response. However, when we treated mice with dasatinib for  8  days,  we  didn’t  release  T  
cells from dasatinib inhibition within the requisite timeframe. Therefore, the T cell 
response was suppressed by the prolonged administration of dasatinib. The comparative 
dynamics of T cell response and drug administration are demonstrated in the below graph 
(Figure 24). In the combination experiment, we found that the therapeutic effect of 8-day 
dasatinib plus anti-OX40 treatment was actually worse than 3-day dasatinib plus anti-
OX40 treatment. This result is consistent with our anticipation that short-term treatment 
elicits strong endogenous T cell response, which can be potentiated by the addition of 
anti-OX40. However, long-term treatment suppresses the development of the T cell 
response,  which  doesn’t  work  as  well  as  short-term treatment when combined with anti-
OX40. These data suggest that optimization of dosing and schedule is a critical factor in 
order to achieve maximal therapeutic effect from combining targeted therapy with 
immunotherapy.   
 
It has been previously believed that sustained target inhibition is a driving principle for 
targeted therapy. However, whether continuous administration of a targeted therapy drug 
is necessary has been recently questioned.  Studies suggest that intermittent or high-dose 
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pulse treatment may provide certain therapeutic advantages. One study showed that, in a 
xenograft model of melanoma positive for the BRAF V600E mutation, persistent 
administration of vermurafenib conferred the development of drug resistance, but 
intermittent treatment prevented the emergence of drug resistance(150). It is speculated 
that selective pressure exerted by prolonged drug treatment, is one of the prerequisites for 
tumor cells acquiring resistance. Therefore, the continuous treatment actually favors the 
development of drug resistance by providing this kind of selective pressure. However, 
intermittent administration of a targeted therapy drug may avoid this effect. Another 
study showed that, in BCR-ABL mutant CML cell lines, 20 minute high-dose pulse 
dasatinib treatment and 48 hour low-dose continuous treatment provided equivalent 
cytotoxicity in vitro. This suggested that once the threshold of target inhibition is 
exceeded,  the  ‘oncogenic  shock’  can  initiate  an  irreversible  cell  death  program  to  commit  
cancer cells to death; and this threshold can be exceeded by either extending the 
treatment time or increasing the inhibition magnitude(151). These results support 
potential clinical utility of intermittent administration of a targeted therapy drug. In 
addition, our study showed that short-term dasatinib treatment can elicit strong anti-tumor 
T cell response, while long-term treatment, which exerts prolonged inhibitory effect on 
immune cells, actually compromised the development of anti-tumor immunity. Therefore, 
in the combination treatment setting, a high-dose pulse or intermittent treatment may be 
superior to continuous administration. 
 
Next we further explored the mechanism of how dasatinib induced a strong anti-tumor T 
cell response. In the P815 model, we found that dendritic cells from dasatinib-treated 
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mice didn’t present more tumor antigen than their counterparts from the untreated control 
group, suggesting that the difference in the magnitude of the T cell response was not 
caused by the first step of T cell priming - which was in contrast with our prior 
hypothesis. Release of a plethora of proteins from dying tumor cells is normally 
considered a good resource of tumor antigens for potential T cell priming. Furthermore, 
several studies have shown that cytotoxic drug regimens could elicit underlying anti-
tumor immune responses (131). However, tumor cells can die in multiple ways, including 
apoptosis, necrosis and autophagy, and there is no consensus about which form of cell 
death is the most capable of stimulating potent anti-tumor immune responses(152). 
Emerging evidence demonstrates that immunogenicity of the tumor death might depend 
on the integration of multiple co-existing signals in a localized context.  Zitvogel and 
colleagues have conducted a series of extensive studies about cell death as induced by 
chemotherapy and irradiation therapy. This has led to a concept known as ‘immunogenic  
cell  death   (ICD)’  which   indicates   that the cells undergoing apoptosis deliver a series of 
immunogenic signals which stimulate APCs to efficiently take up the tumor antigens, 
process and present them to T cells, thereby eliciting an immune response against the 
tumor (153). Several immunogenic factors delivered by cells undergoing ICD have been 
identified, including exposure of an ER chaperone protein Calreticulin (CRT) on the 
tumor cell surface and the release of ATP and HMGB1, a well-known damage-associated 
molecular pattern (DAMP) protein (154-156). In light of these results, it is possible that 
dasatinib-induced P815 tumor cell death is not inducing ICD. Another possibility is, the 
antigen-presenting capability of DCs is compromised by dasatinib. The effect of dasatinib 
on the DC function of taking up, processing, and presenting antigen has not yet been 
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reported. But there are studies showing that c-KIT activation in DC enhanced the 
production of IL-6 which in turn promoted Th2/ Th17 responses; blocking c-KIT 
signaling helped skew the response toward Th1 direction, suggesting that c-KIT signaling 
might play a critical role in regulating DC function (157). It also has been shown that 
imatinib can inhibit DC differentiation and priming of CTL responses in vitro, but it is 
unclear whether this could be attributed to the inhibition of c-KIT (158, 159). 
Considering dasatinib and imatinib have partially overlapping kinase target spectrums, it 
is possible that dasatinib also suppresses DC function, and the increased tumor antigen 
released after dasatinib treatment was offset by the inhibitory effect of dasatinib on DC 
function. The exact effect of dasatinib on the immunogenicity of P815 tumor death and 
DC function needs to be further studied. However, in this model the enhanced T cell 
priming did not appear to be caused by increased tumor antigen presentation. 
 
Next, we examined Treg levels in these mice, since dasatinib has been shown to inhibit 
Treg proliferation and suppressive function in vitro (139). Tregs can suppress immune 
effector cells and are critical mediators of cancer immune tolerance. Tregs were first 
identified by the Sakaguchi group as a CD4+ T cell subset expressing Foxp3 and high 
levels of CD25 (160-162). They comprise about 5-10% of the peripheral CD4+ T cell 
population. Regulatory T cells can be further classified as naturally occurring Treg 
(nTreg) which are derived from the thymus and induced Treg (iTreg) which develop from 
conventional CD4+ T cells. Tregs can strongly inhibit the activation, expansion, cytolytic 
activity and cytokine production of effector T cells. Mechanisms for the suppressive 
function of Tregs include expression of IL-10 and TGF-β, releasing granzymes and 
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perforin to induce the apoptosis of effector cells, and producing cAMP and adenosine to 
disrupt the normal metabolism of effector cells. In addition, Tregs can also modulate the 
activation status of dendritic cells to indirectly suppress effector T cell priming (163-165). 
Many studies have shown that cancer cells can subvert immune-mediated control by 
promoting and recruiting Tregs, and Treg levels in circulation or tumor 
microenvironment are inversely correlated with the prognosis of patients with various 
types of cancer(166). Therefore, down-regulation of Treg levels or function could 
directly influence the magnitude of an anti-tumor immune response and the outcome of 
anti-tumor therapy (167-173).  
 
In our study, we found that Treg cells were more sensitive than effector T cells to 
dasatinib inhibition, and 3-day dasatinib treatment significantly decreased the Treg/CD4+ 
and Treg/CD8+ ratios in the blood of the mice. The intratumoral Treg levels were also  
down-regulated following dasatinib treatment.  When we pre-treated mice with vehicle or 
dasatinib for 3 days then gave P1A peptide-pulsed DC vaccine, the antigen-mediated 
CD8+ T cell response was significantly higher in dasatinib-pre-treated mice. This 
experiment suggests that suppression of Tregs might be one mechanism mediating the 
enhanced anti-tumor T cell response after dasatinib treatment. The homeostatic 
proliferation, survival and function of Treg cells depends on multiple external signals, 
including TCR, IL-2R, CD28, CTLA-4 and other less-characterized pathways (174). Lck, 
a tyrosine kinase that plays a critical role in the TCR signaling pathway, is also known to 
be important for Treg homeostasis and function. Mice with a conditional null allele of 
Lck in the Treg compartment have significantly reduced number of Treg cells, and their 
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proliferation capability and immunosuppressive function are also impaired (175).  Since 
Lck activity is strongly inhibited by dasatinib in effector T cells (137), it is possible that 
dasatinib also inhibits Lck activity in Treg cells which leads to the reduced number and 
function of those cells. It is also possible that other unidentified tyrosine kinases involved 
in Treg proliferation, survival and function are inhibited by dasatinib, which will require 
further experimental exploration to determine. Activation of the OX40 signal has been 
shown to attenuate the suppressive function of Treg cells (99-101); Consistent with this, 
our experiment showed that dasatinib combined with anti-OX40   exerted   a   ‘dual  
inhibition   ’effect   on   the   function   of   Treg   cells.   Therefore,   an   additional   benefit   of 
combining these two agents together may lie in the down-regulation of Treg levels and 
function. 
 
One may also speculate that other tyrosine kinase inhibitors may also have a similar 
effect of enhancing underlying anti-tumor immune response when being administered 
properly, since many of them have been shown to exert inhibitory effects on 
immunosuppressive cells. For example, imatinib, sunitinib and sorafeinib have all been 
shown to inhibit Treg proliferation or suppressive function(130, 176, 177). However, 
they have also been reported to negatively interfere with T effector cells(178). 
Considering these drugs have partially overlapping target spectrum with dasatinib, given 
that they all inhibit Src family members, the underlying molecular mechanisms mediating 
the immunomodulatory effect may be similar. Additionally, sunitinib is known to 
potently suppress MDSC function and accumulation in cancer patients.(130). Whether 
these drugs can also be combined with immunotherapy to achieve synergistic therapeutic 
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effect requires further study. We speculate that one advantage of dasatinib, compared to 
other tyrosine kinase inhibitors, is its short-half life. The overall mean terminal half-lives 
of other tyrosine kinase inhibitors are typically 2 to 3 days, while dasatinib has a half-life 
of 5-6 hours.(39). This may prove to be therapeutically advantageous when combined 
with immunotherapy. Because prolonged half-life may lead to prolonged 
immunosuppression, short half-life may lead to transient immunosuppression. Feasible 
combinations of long half-life tyrosine kinase inhibitors with immunotherapy need 
further experimental exploration. Again, the dosing and schedule is an essential factor to 
consider in combining long half-life tyrosine kinase inhibitors with immunotherapy. 
 
We also explored how dasatinib affected the immune microenvironment of P815 tumors. 
From microarray and luminex assays, we found that IL-10 levels were significantly 
down-regulated at the tumor site. IL-10 has been shown to exert pleiotropic effects on 
both adaptive and innate immune responses, and it is generally considered a negative 
regulator of anti-tumor immune responses. Many different types of cancer cells directly 
produce IL-10, and systemic IL-10 level is negatively correlated with prognosis in 
multiple cancer types (179-183). IL-10 is known to impair the antigen presenting 
capability of DCs by suppressing the surface expression of HLA class II molecules and 
certain positive costimulatory molecules (for example, CD80 and CD86),  and up-
regulating certain negative costimulatory molecules (for example, PD-L1)(184, 185). It 
has also been shown that IL-10-treated dendritic cells can induce T cell anergy after 
antigen presentation (186). IL-10 can also down-regulate HLA class I and class II in 
certain types of cancer, which reduces tumor recognition by cytolytic T cells (187, 188). 
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IL-10 can suppress T cell proliferation by reducing the production of IL-2 and IFN-γ 
(189).  Furthermore, IL-10 is not only the major mediator of Treg suppressive function, 
but also involved in the proliferation and differentiation of certain subsets of Tregs(190-
192). In addition, IL-10 can enhance HLA-G surface expression on tumor cells, which 
prevents tumor lysis by NK cells (193). Therefore, tumor-derived IL-10 has long been 
considered as an important factor in cancer immune escape. Our in vivo experiments also 
showed that blocking IL-10 could ameliorate immunosuppression and enhance the 
endogenous anti-tumor T cell response. Since P815 itself produces significant amounts of 
IL-10, eradication of tumor cells would directly lead to a decrease of this 
immunosuppressive cytokine within the tumor microenvironment. This could be an 
important contributing factor to the tumor-specific T cell response induced upon 
dasatinib treatment. The ability to relieve immune suppression could be considered as 
another beneficial mechanism provided by targeted therapy drugs. 
 
Recently emerging evidence suggests links between oncogenic signaling and 
immunosuppression in cancer. For example, MAPK signaling pathway in BRAF mutant 
melanoma cell lines has been shown to promote the production of IL-10, VEGF and IL-6, 
which are immunosuppressive soluble factors, and overexpression of PD-L1 in tumor 
microenvironment(129, 144). Therefore, MAPK signaling is considered as a critical 
mechanism through which melanoma immune evasion is mediated. PTEN loss and 
hyperactivity of PI3K/Akt pathway have been shown to increase PD-L1 expression in 
colon cancer cell lines and melanoma cell lines(194, 195). STAT3 activation has been 
shown to be associated with the expansion and function of MDSC in the tumor 
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microenvironment(196). The MAPK pathway, PI3K/Akt pathway and JAK/STAT 
pathway are all frequently activated in cancers and c-KIT signaling has been shown to 
activate these pathways in various types of cancer cells.(17). Therefore, it is possible that 
the down-regulation of c-KIT could directly suppress the activation of these pathways, 
thereby alleviating immunosuppression in the tumor microenvironment. Although this 
has not been observed in our tumor model, exploration of potential links between c-KIT 
oncogenic signaling and cancer immunosuppression in other cancer models is still 
desirable. These studies can lead to a better understanding of the signaling pathways 
driving immunosuppression, and could pave the way for utilizing c-KIT inhibitors to 
subvert cancer immunosuppression in combination treatment settings. 
 
Effective T cell priming alone is not sufficient to induce potent anti-tumor immune 
responses, because adequate migration of CTLs into the tumor microenvironment is also 
essential for tumor cell eradication. For example, cancer vaccines can successfully induce 
the generation of large numbers of tumor-specific T cells in the circulation, but still 
usually fail to provide significant therapeutic benefit (197). In addition, extensive 
infiltration of tumor-reactive immune cells is often correlated with better prognosis in 
patients. For example, in melanoma, ovarian and colon cancers, CD8+ T cell infiltration 
can serve as a strong positive prognostic marker (198, 199).   These lines of evidence 
demonstrate that presence of CTL within the tumor microenvironment is crucially 
important for an effective anti-tumor response. 
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Two recent studies have shown that administration of agonistic anti-OX40 antibody 
potentiated CD8+ T cell infiltration and suppressed Treg infiltration in murine tumors (88, 
104).  In our study, anti-OX40 treatment did not significantly affect the clonal expansion 
of tumor-specific T cells, but we did observe increased percentages and absolute numbers 
of CD8+ T cells at tumor sites in mice from the anti-OX40 treatment group, which is 
consistent   with   the   ‘enhancing-migration’   function   suggested   by the above-mentioned 
studies. In addition, the combination of dasatinib and anti-OX40 increased the 
percentages and absolute numbers of P1A-specific T cells, and decreased the Treg/CD8+ 
T cell ratio within the tumor microenvironment.  Therefore, the major effect of anti-
OX40 in this mouse model seems to be potentiating anti-tumor T cell responses by 
enhancing the recruitment of CTL into tumor microenvironment. Considering that 
impaired CTL trafficking has been shown to be a rate-limiting step for cancer 
immunotherapy, anti-OX40 might be a promising therapeutic agent to boost the clinical 
efficacy of this approach. 
 
T cell migration is a complicated multi-step process which involves a number of 
molecules. The repertoire of chemokines is a key factor determining the migration and 
infiltration of T cells into tumor sites. In particular, the CXCR3 - CXCL9/10/11 axis is 
known to play an important role in CD8+ T cell chemotaxis and homing to tumors. 
CXCL9, 10 and 11 are T cell chemoattractants induced by IFN-γ (200), and CXCR3 is a 
chemokine receptor preferentially expressed by Th1 cells. Ligation of CXCR3 with those 
chemokines induces integrin activation and cellular cytoskeletal changes which promote 
the chemotactic migration of T cells (201). In our study, we demonstrated that this 
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combinatorial regimen significantly up-regulated the expression of CXCL9, 10 and 11 at 
tumor sites. Furthermore, high levels of those cytokines correlated well with the high 
levels of tumor-specific T cells in tumors treated with the combinatorial regimen, which 
is consistent with our prediction that the tumor microenvironment is made more 
permissive due to the induction of these cytokines.  At this time, the exact mechanism by 
which the combination of dasatinib and anti-OX40 enhances the level of Th1 cytokines is 
not clear. But there is one report showing that activating the OX40 signaling pathway can 
directly induce the expression of CXCL9 by vascular endothelial cells at the tumor site, 
suggesting that one possible mechanism of anti-OX40 enhancing CTL trafficking is 
through augmenting Th1 chemokine signals. Our results support a model that dasatinib, 
OX40, CTL, IFN-γ  and  CXCL9, 10 and 11 compose a positive feedback loop in which 
dasatinib leads to increased tumor-specific T cells in the circulation; the OX40 signal 
enhances the migration of CTL into the tumor sites by inducing the expression of CXCL9; 
large amounts of IFN-γ  are produced after CTLs encounter antigen on tumor cells; IFN-γ  
further up-regulates CXCL9, 10 and 11, which bring more CTLs into the tumor 
microenvironment and produces more IFN-γ  and  IFN-γ-induced chemokines (Figure 25).  
Therefore, treatment with dasatinib plus anti-OX40 promotes T cell responses at both the 
priming and trafficking stages, explaining the superior therapeutic effect of this 
combination. 
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Figure 24 Comparative dynamics of T cell response and dasatinib administration. 
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Figure 25 Mechanism underlying the anti-tumor effect of the combination of 
dasatinib and anti-OX40.  
Tumor antigens are phagocytosed by mDCs which present them to T cells and drive the 
activation and expansion of tumor-specific T cells. Dasatinib suppresses Treg cells and 
down-regulates IL-10 levels in the tumor microenvironment, which helps T cell prime 
better. Anti-OX40 also exerts inhibitory effect on Treg cells. Anti-OX40 provides a 
costimulatory signal, which augments the migration of circulating tumor-specific 
cytotoxic T cells into the tumor microenvironment. CTL release IFN-γ after encounter 
tumor cells and IFN-γ up-regulates the expression levels of CXCL9,10 and 11 which 
further bring more CTL into tumor microenvironment. Tumor cells are eradicated by the 
tumor antigen-specific T cells in the tumor microenvironment. 
 
This is a modified version of a figure originally published in Oncoimmunology. Yang Y, 
Lizée G, Hwu P. Strong emerging rationale for combining oncogene-targeted agents with 
immunotherapy. Oncoimmunology. 2013 Feb 1;2(2):e22730. © Landes Bioscience 
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4.2 Future directions 
 
The results presented in this thesis together with other related studies give rise to several 
other questions calling for further validation. Studies analyzing the interaction between 
targeted therapy drugs and the anti-tumor immune response will provide guidance to 
clinical practice in the future. 
 
Treg cells are one of the most important immunosuppressive components for tumor-
induced tolerance. Numerous studies have demonstrated the benefit of eliminating Treg 
cells for improving the efficacy of cancer immunotherapy. In this study, we show that 
dasatinib has strong anti-Treg function, which might make this drug a good candidate for 
integration into cancer immunotherapy strategies. However, the molecular mechanism of 
dasatinib-mediated Treg inhibition is poorly understood. It is not known whether Lck is 
the molecular mediator of this inhibitory effect. Since Tregs are more sensitive to 
dasatinib inhibition than effector T cells, do Treg cells have higher Lck dependence than 
T effector cells? Are there any other tyrosine kinases involved? Further work 
characterizing the proteomic and transcriptional changes after dasatinib treatment in Treg 
cells will help to answer those questions.  
 
It also would be valuable to monitor the level and function of T effector cells and Treg 
cells  from  patients  treated  with  dasatinib.  This  will  ascertain  if  the  similar  ‘low  Treg/  T  
effector  ratio’  window  exists in the bodies of human beings to facilitate development of 
immune response against tumor. Phenotypic characterization of those cells will also help 
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to determine the potential clinical value of combining this drug with immunotherapy. 
More pre-clinical and clinical studies are needed to determine the optimal doses and 
schedules of dasatinib administration before applying the combination in patient 
treatment. Since there are other tyrosine kinase inhibitors - for example imatinib, 
sorafenib and sunitinib - that show suppressive effect on Tregs, these drugs are also 
potentially able to reverse immunosuppression in the combination therapy setting, 
although this awaits further experimental validation. 
 
With the advent of the animal model in which mice spontaneously develop GIST owing 
to the mutant c-KIT gene, scientists have been able to study the interaction between 
imatinib and the host anti-GIST immune response (128). It would be interesting to try the 
combination of imatinib/dasatinib and anti-OX40 to observe the therapeutic effect and 
see whether the a similar positive feedback loop composed of targeted agent, CTL, IFN-γ  
and Th1 cytokines can be generated in this model. Since a humanized anti-OX40 
antibody is now available, these studies will pave the way for translating the combination 
of c-KIT inhibitor and anti-OX40 into GIST clinical trials. Since melanoma is the most 
responsive cancer to immunotherapy, further development of mouse c-KIT mutant 
melanoma models is desirable, which will offer opportunities of conducting preclinical 
studies testing the feasibility of using this combination to treat melanoma patients. 
 
Our work and that of others have shown that agonistic OX40 antibody can boost the 
migration of CTL into the tumor microenvironment. However, the exact mechanism 
underlying this phenomenon is largely unknown. It would be interesting to characterize 
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OX40 expression by the various subsets of cells in both human and murine tumor 
microenvironments and study the phenotypic changes to these cells before and after 
OX40 activation both in vitro and in vivo. OX40 or OX40L conditional knockout mice 
could be utilized to identify the cellular mediators for the enhanced migration of CTL to 
the tumor site induced by OX40 activation. Those studies would help to evaluate the 
potential clinical utility of applying agonistic anti-OX40 antibody for cancer treatment.  
 
Several recent publications have reported that combinations of targeted therapy and 
immunotherapy provide a synergistic therapeutic effect in various tumor models. BRAF 
inhibitor PLX4032 was shown to synergize with adoptive T cell therapy in a melanoma 
mouse model (202).  Another c-KIT inhibitor imatinib combined with anti-CTLA-4 
provided superior anti-tumor effect in a GIST mouse model (128). The result of a GIST 
clinical trial combining imatinib and IFN-α  also  appears very promising (203). However, 
more studies are needed to understand the interaction between various targeted therapy 
drugs and host immune responses. Most importantly, optimization of the dosing and 
scheduling for these treatments is needed to achieve maximal therapeutic effect. More 
speculatively, future animal studies and clinical trials can be conducted to combine 
cytokine-based therapy, cancer vaccines, adoptive T cell therapy and antibodies against 
other co-stimulatory or checkpoint molecules with molecular targeted drugs. 
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Chapter 5. Methods and materials 
 
Cell lines, reagents, and animals 
P815 murine mastocytoma cells were obtained from ATCC (Manassas, VA). All tumor 
cell lines were maintained in MEM (Life Technologies, Grand Island, NY) with 10% 
FBS (Atlanta Biologicals, Lawrenceville, GA)  and  100μg/ml  Normocin  (Invivogen,  San  
Diego, CA). DBA/2 mice, 6-10 weeks old, were purchased from National Cancer 
Institute (Bethesda, MD) and maintained in a pathogen-free animal facility at M. D. 
Anderson Cancer Center. P1CTL transgenic mice were provided by Dr. Yang Liu 
(University of Michigan Health System, Ann Arbor, MI). Mice were handled in 
accordance with protocols approved by the Institutional Animal Care and Use Committee. 
Dasatinib was purchased from LC Laboratories (Woburn, MA) and dissolved in vehicle 
(50% Polyethylene glycol, 50%H2O) before gavage. Anti-OX40 antibody was purchased 
from Harlan (Indianapolis, IN). CD8 depletion antibody (clone HB129/116-13.1), CD4 
depletion antibody (clone GK1.5), anti-IL-10 blocking antibody (clone JES5-2A5), anti-
CTLA-4 antibody (clone 9H10), anti-PD-1 antibody (clone J43) and Rat IgG 2b isotype 
control antibody were purchased from Bioxcell (West Lebanon, NH).   
 
Reagents for flow cytometric analysis 
Flow cytometric analysis was performed using the following antibodies: FITC-
conjugated   αCD3,   APC-conjugated   αCD8,   PE-conjugated   αIFN-γ,   FITC-conjugated 
αCD11c,  APC-conjugated   αCD11b,  Percp-Cy5.5-conjugated   αCD11b,  APC-conjugated 
αAnnexin  V   and  Annexin  V   binding buffer were purchased from BD Bioscience (San 
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Jose, CA); APC-conjugated   αFoxp3,   PerCP-Cy5.5-conjugated   αCD25,   PE-conjugated 
αCD4,   FITC-conjugated   αCD8,   Pacific   Blue-conjugated   αCD8,   APC-conjugated 
αCD117, APC-conjugated  αGr-1, FITC-conjugated  αLy6C  and 7-AAD viability staining 
solution were purchased from eBioscience (San Diego, CA); PE-conjugated P1A 
tetramer was synthesized at the MHC Tetramer Production Facility of Baylor College of 
Medicine (Houston, TX). IFN-γ   and   Treg   staining   was   performed   according to the 
protocol provided by the manufacturers (BD Bioscience and eBioscience). Cells were 
analyzed using the BD Caton II flow cytometer, with data analyzed by using BD Diva 
software. 
 
Tumor inoculation and immunotherapy 
DBA/2 mice were subcutaneously inoculated with 2×106 P815 tumor cells on the left 
abdominal wall on day 0. Mice with moderate tumor size were selected and divided into 
different groups on day 8 (6-10 mice in each group). Tumor-bearing mice were treated 
with vehicle or dasatinib (150mg/kg) on day 8, 9 and 10 by gavage. In the combination 
treatment experiments, mice were also injected intraperitoneally with anti-OX40 antibody 
(200μg/mice),  anti-PD-1  antibody  (200μg/mice),  anti-CTLA-4  antibody  (100μg/mice)  on  
day 10 and 13. Tumor growth was monitored by measuring the perpendicular diameters 
of tumors. Mice were sacrificed when the tumor diameters exceeded 20 mm. For CD4+/ 
CD8+T cell-depletion experiments, tumor-bearing mice were injected intraperitoneally 
with  200μg  of  monoclonal  antibodies starting from day 8 once a week. Rat IgG was used 
as control antibody. Depletion of CD4+ and CD8+T cells was confirmed by analyzing 
the peripheral blood of the mice by flow cytometry. For IL-10 blocking experiment, 
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tumor-bearing mice were injected intraperitoneally   with   200μg   of   IL-10 blocking 
antibody starting from day 8 twice a week.  
 
Monitoring tumor antigen-specific T cell response 
On   day   14,   18,   21   and   26,   50μl   of   peripheral   blood   was   collected   by   using   tail-clip 
method and then treated with ACK lysis buffer (Cambrex, Walkersville, MD) for 5 
minutes   to   deplete   the   red   blood   cell.   Cells   were   stained   with   αCD3,   αCD8   and   P1A  
tetramer antibodies. For IFN-γ   intracellular   staining,   cells   were   stimulated   with   or  
without   10μg/ml   P1A   or   P1E   peptide   in   the   presence of 1:1000 Golgiplug (BD 
Bioscience)   for   6   hours.   Cells  were   then   collected   and   stained  with   αCD3,   αCD8   and  
αIFN-γ  antibodies.  The  percentage  of  antigen-specific T cells was analyzed by using flow 
cytometry. In another experiment, collected peripheral blood cells were stimulated with 
or without P1A or P1E peptide (Peptides International, Louisville, KY) for 24 hours. The 
supernatants were harvested and the concentration of IFN-γ  was  detected  by  ELISA.  The  
IFN-γ  ELISA  kit  was  purchased   from  Biolegend   (San Diego, CA) and the experiments 
were  conducted  according  to  manufacturer’s  instruction. 
 
T cell CFSE proliferation assay and IFN-γ  release  assay 
Splenocytes from P1CTL transgenic mice were harvested and labeled with 1µM CFSE 
(Invitrogen, Carlsbad, CA) for 5 minutes at 37 ºC. After being washed with PBS, 
splenocytes  were  cultured  with  10μg/ml  P1A  peptide  in  the  presence  of  0nm,  1nm,  5nm,  
10nm, 25nm or 50nm dasatinib. Two days later, CFSE dilution was analyzed by BD 
Caton II flow cytometer. Splenocytes were also harvested and cultured  in the presence of  
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250 units/ml human interleukin-2 Proleukin (Chiron, Emeryville, California) and 0.3 
μg/ml  anti-mouse CD3 (BD Bioscience, San Jose, CA) for 7 days. More than 95% of the 
cultured cells were CD8+ P1A-specific T cells  after  7  days’  culture.  Then  the  effector  T  
cells were cultured alone or with P815 tumor cells as 1:1 ratio or in the presence of 10 
μg/ml   P1A   peptide   for   24   hours   in   96-well round bottom plates. Supernatants were 
harvested and concentration of IFN-γ was detected by ELISA.  
 
Dendritic cell antigen presenting assay 
Mice were treated with vehicle or dasatinib for 2 days. On day3, left inguinal lymph 
nodes which are the tumor draining lymph nodes and right inguinal lymph nodes which 
are the non-draining lymph  nodes  were  harvested  and  stained  with  αCD11c  and  αCD11b.  
Double positive cells were sorted out by FACS and cocultured in 96-well round bottom 
plate together with P1A-specific T cells which had been cultured with IL-2 and anti-CD3 
for 7 days. 1:1000 Golgiplug was added in the culture. Eight hours later, cells were 
collected  and  stained  with  αCD8  and  αIFN-γ  antibodies  and  analyzed  by  flow  cytometry. 
 
Dendritic cell vaccination 
Murine bone marrow cells were grown in complete medium with 100ng/ml GM-CSF for 
8  days  then  stimulated  with  1μg/ml  LPS  for  1  day.  Non-adherent cells were collected and 
resuspended in Opti-MEM Medium (Life Technologies, Grand Island, NY) at a 
concentration of 2×106 cells/ml,   and   pulsed  with   10  μg/ml  P1A  peptide for 4 hours at 
37°C.  On day-3, 3 million splenocytes from P1CTL transgenic mice were transferred 
into DBA/2 mice via intravenous injection. Then mice were treated with vehicle or 
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dasatinib for 3 days. On day 0, 1 million P1A peptide-pulsed DCs were transferred into 
DBA/2 mice. Peripheral blood was collected on day 7 for flow cytometric analysis. 
 
C-KIT knockdown 
C-KIT was knocked down by ON-TARGETplus SMARTpool (Thermo Scientific, 
Pittsburgh,  PA). P815 cells were transfected with the Cell Line Nucleofector Kit T 
(Lonza, Allendale, NJ) by using program C-013 according to manufacturer’s  instruction. 
Concentrations of the mouse c-KIT siRNA pool and non-targeting  pool were 2µM. And 
2μg  of  pmaxGFP  vector  in  the  kit  was  also  used  for  transfection  to  check  the  transfection  
efficiency. Flow cytometric analysis 24 hours after electroporation indicated that 
transfection efficiency was higher than 80%.  24 hours later, the cells were stained with 
αCD117  (c-KIT) antibody and analyzed by flow cytometry. 
 
Taqman Realtime PCR for C-KIT 
Cells were harvested 24 hours after siRNA transfections. RNA was isolated by using 
RNAeasy   mini   Kit   (Qiagen,   Valencia,   CA)   according   to   manufacturer’s   instruction. 
CDNA synthesis was done by using Cloned AMV first-strand cDNA synthesis kit 
(Invitrogen, Rockville, MD ). Taqman  Realtime PCR was carried out using 7500 Fast 
Realtime PCR machine (Applied Biosystems, Foster city, CA). Primer for c-KIT and 
GAPDH were purchased from life technologies(Grand Island, NY). Data analysis was 
performed using 7500 Fast system software. 
 
Microarray analysis and Luminex assay 
 115 
P815 tumors were harvested 24 hours after vehicle or dasatinib treatment. There were 2 
tumors in each group. Cultured P815 cells were harvested 24 hours and 36 hours after 
being transfected with siRNA. P815 tumor cells were also treated with DMSO or 25nm 
dasatinib in vitro for 24 hours and then collected. Samples were snap-frozen in liquid 
nitrogen and sent to Expression Analysis (Durham, NC) for microarray analysis by using 
the Mouse WG6 arrays (Illumina, San Diego, CA).  In P815 tumor samples, to identify 
differentially expressed genes between tumors treated with vehicle and tumors treated 
with dasatinib, we calculated the mean of the QS-normalized, background-subtracted, 
log2 transformed signals of the 2 samples. Heatmaps were made by Cluster 3.0 and 
viewed by TreeView, displaying the 20 most differentially expressed immune-related 
genes selected based on the fold change of the mean. For Luminex assay, tumors were 
harvested after 3-day dasatinib treatment. Tumor masses were homogenized and then 
sonicated in lysis buffer which contained protease inhibitors. After centrifuge, the tumor 
lysates were used for the analysis of multiple cytokines by multiplex Luminex assay 
(Aushon Biosystems, Woburn, MA).The experiment was conducted according to 
manufacturer’s  instruction . 
 
Immunohistochemistry 
Tumors were harvested after 3-day vehicle or dasatinib treatment. Samples were 
embedded in OCT and snap-frozen in liquid nitrogen. Immunohistochemistry was done 
by Research Histopathology Facility at M. D. Anderson.  
 
Harvest of tumor infiltrating lymphocytes 
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On day 16, tumors were harvested and dissected into fragments by cutting, and then 
digested in tumor digestion buffer for 2 hours at 37ºC. The tumor digestion buffer was 
made by dissolving 1mg/ml collagenase, 100µg/ml hyaluronidase and 20mg/ml DNase 
(Sigma-Aldrich, St. Louis, MO) in RPMI medium. Then tumor digests were filtered 
through 70µm nylon mesh. Cell suspensions were layered over the Lympholyte-M 
density separation medium (Cedarlane, Hornby, Ontario, Canada) and centrifuged at 
1000g for 20 minutes. Lymphocyte layers at the interface were isolated and analyzed by 
flow cytometry.  
 
SYBR Green Realtime PCR for chemokines 
Total RNA was isolated from tumors on day 16 after tumor inoculation by using 
RNAeasy mini Kit (Qiagen, Valencia, CA) according to the protocol provided by the 
manufacturer. Cloned AMV first-strand cDNA synthesis kit (Invitrogen, Rockville, MD ) 
was used for cDNA synthesis. SYBR Green Realtime PCR was done by using Bio-Rad 
C1000 Thermal cycler (Bio-rad, Hercules, CA ). And the panel of chemokine primers is 
shown below (Table 4). The chemokines on the Realtime PCR panel include CCL1-13, 
CCL17, CCL19-22, CCL24-25, CCL27-28, CXCL1-2, CXCL4-5, CXCL7, CXCL9-16, 
XCL1 and CX3CL1. GAPDH was used as the normalization reference gene. Data 
analysis was performed using Bio-Rad CFX manager software. 
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Table 4 List of the chemokine primers for realtime PCR 
   
This table was originally published in Cancer Research. Peng W, Liu C, Xu C, Lou 
Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizée G, Radvanyi L, Hwu P. PD-1 
blockade enhances T-cell migration to tumors by elevating IFN-γ  inducible  
chemokines. Cancer Research. 2012; 72(20): 5209-18. © the American Association 
for Cancer Research 
.  
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Treg suppression assay 
Mice were treated with 3 doses of vehicle or dasatinib (150 mg/kg) and 1 dose of anti-
OX40 (200 µg/mice). After that, splenocytes of the mice were collected and stained with 
αCD4,  αCD8,  αCD25  antibodies.  CD4+ CD25high cells from the 4 different groups were 
sorted out as Treg cells by flow cytometry, and CD8+ cells were sorted out as effector T 
cells. Effector T cells were labeled with 1µM CFSE for 5 minutes at 37°C. Sorted Treg 
cells and effector T cells were co-cultured at a 2:1 ratio in 96-well round bottom plate 
with non-T cell splenocytes as APCs, 30IU/ml IL-2  and  0.1μg/ml  αCD3.  Three  days  later,  
cells were analyzed for CFSE dilution by flow cytometric analysis. 
 
Statistical analysis 
Data are represented as mean ± SEM. The statistical differences between different groups 
were determined by the Student's T test or one way ANOVA test in GraphPad Prism 
software. Mouse survival between groups was compared by using the Log-rank test in 
GraphPad Prism software.  
  
 119 
Bibliography 
 
1. Majidi, J., J. Barar, B. Baradaran, J. Abdolalizadeh, and Y. Omidi. 2009. Target 
therapy of cancer: implementation of monoclonal antibodies and nanobodies. 
Hum Antibodies 18:81-100. 
2. Ohnuma, K., and C. Morimoto. 2010. [Targeted therapy by monoclonal 
antibodies]. Nihon Rinsho 68:1841-1847. 
3. Altundag, K., F. J. Esteva, and B. Arun. 2005. Monoclonal antibody-based 
targeted therapy in breast cancer. Curr Med Chem Anticancer Agents 5:99-106. 
4. Rao, A. V., and K. Schmader. 2007. Monoclonal antibodies as targeted therapy in 
hematologic malignancies in older adults. Am J Geriatr Pharmacother 5:247-262. 
5. Banerjee, S., and H. Flores-Rozas. 2010. Monoclonal antibodies for targeted 
therapy in colorectal cancer. Cancer Biol Ther 9:563-571. 
6. Imai, K., and A. Takaoka. 2006. Comparing antibody and small-molecule 
therapies for cancer. Nat Rev Cancer 6:714-727. 
7. Weiner, L. M., and H. Borghaei. 2006. Targeted therapies in solid tumors: 
monoclonal antibodies and small molecules. Hum Antibodies 15:103-111. 
8. Chahrour, O., D. Cairns, and Z. Omran. 2012. Small molecule kinase inhibitors as 
anti-cancer therapeutics. Mini Rev Med Chem 12:399-411. 
9. Bickenbach, K., R. Wilcox, J. Veerapong, H. L. Kindler, M. C. Posner, A. 
Noffsinger, and K. K. Roggin. 2007. A review of resistance patterns and 
phenotypic changes in gastrointestinal stromal tumors following imatinib 
mesylate therapy. J Gastrointest Surg 11:758-766. 
 120 
10. Rini, B. I., and M. B. Atkins. 2009. Resistance to targeted therapy in renal-cell 
carcinoma. Lancet Oncol 10:992-1000. 
11. Smalley, K. S. 2010. PLX-4032, a small-molecule B-Raf inhibitor for the 
potential treatment of malignant melanoma. Curr Opin Investig Drugs 11:699-706. 
12. Vidal, L., G. Attard, S. Kaye, and J. De Bono. 2004. Reversing resistance to 
targeted therapy. J Chemother 16 Suppl 4:7-12. 
13. Ashman, L. K., and R. Griffith. 2013. Therapeutic targeting of c-KIT in cancer. 
Expert Opin Investig Drugs 22:103-115. 
14. Qiu, F. H., P. Ray, K. Brown, P. E. Barker, S. Jhanwar, F. H. Ruddle, and P. 
Besmer. 1988. Primary structure of c-kit: relationship with the CSF-1/PDGF 
receptor kinase family--oncogenic activation of v-kit involves deletion of 
extracellular domain and C terminus. EMBO J 7:1003-1011. 
15. Mol, C. D., K. B. Lim, V. Sridhar, H. Zou, E. Y. Chien, B. C. Sang, J. 
Nowakowski, D. B. Kassel, C. N. Cronin, and D. E. McRee. 2003. Structure of a 
c-kit product complex reveals the basis for kinase transactivation. J Biol Chem 
278:31461-31464. 
16. Lev, S., J. M. Blechman, D. Givol, and Y. Yarden. 1994. Steel factor and c-kit 
protooncogene: genetic lessons in signal transduction. Crit Rev Oncog 5:141-168. 
17. Ronnstrand, L. 2004. Signal transduction via the stem cell factor receptor/c-Kit. 
Cell Mol Life Sci 61:2535-2548. 
18. Liang, J., Y. L. Wu, B. J. Chen, W. Zhang, Y. Tanaka, and H. Sugiyama. 2013. 
The C-kit receptor-mediated signal transduction and tumor-related diseases. Int J 
Biol Sci 9:435-443. 
 121 
19. Lennartsson, J., and L. Ronnstrand. 2006. The stem cell factor receptor/c-Kit as a 
drug target in cancer. Curr Cancer Drug Tar 6:65-75. 
20. Lennartsson, J., and L. Ronnstrand. 2012. Stem cell factor receptor/c-Kit: from 
basic science to clinical implications. Physiol Rev 92:1619-1649. 
21. Fletcher, J. A., and B. P. Rubin. 2007. KIT mutations in GIST. Curr Opin Genet 
Dev 17:3-7. 
22. He, H. Y., W. G. Fang, H. H. Zhong, Y. Li, J. Zheng, J. Du, W. J. Heng, and B. Q. 
Wu. 2006. [Status and clinical implication of c-kit and PDGFRA mutations in 165 
cases of gastrointestinal stromal tumor (GIST)]. Zhonghua Bing Li Xue Za Zhi 
35:262-266. 
23. Joensuu, H. 2006. Sunitinib for imatinib-resistant GIST. Lancet 368:1303-1304. 
24. Ugurel, S., R. Hildenbrand, A. Zimpfer, P. La Rosee, P. Paschka, A. Sucker, P. 
Keikavoussi, J. C. Becker, W. Rittgen, A. Hochhaus, and D. Schadendorf. 2005. 
Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 
92:1398-1405. 
25. Kim, K. B., O. Eton, D. W. Davis, M. L. Frazier, D. J. McConkey, A. H. Diwan, 
N. E. Papadopoulos, A. Y. Bedikian, L. H. Camacho, M. I. Ross, J. N. Cormier, J. 
E. Gershenwald, J. E. Lee, P. F. Mansfield, L. A. Billings, C. S. Ng, C. 
Charnsangavej, M. Bar-Eli, M. M. Johnson, A. J. Murgo, and V. G. Prieto. 2008. 
Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J 
Cancer 99:734-740. 
26. Wyman, K., M. B. Atkins, V. Prieto, O. Eton, D. F. McDermott, F. Hubbard, C. 
Byrnes, K. Sanders, and J. A. Sosman. 2006. Multicenter phase II trial of high-
 122 
dose imatinib mesylate in metastatic melanoma - Significant toxicity with no 
clinical efficacy. Cancer 106:2005-2011. 
27. Curtin, J. A., K. Busam, D. Pinkel, and B. C. Bastian. 2006. Somatic activation of 
KIT in distinct subtypes of melanoma. Journal of Clinical Oncology 24:4340-
4346. 
28. Handolias, D., A. L. Hamilton, R. Salemi, A. Tan, K. Moodie, L. Kerr, A. 
Dobrovic, and G. A. McArthur. 2010. Clinical responses observed with imatinib 
or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer 
102:1219-1223. 
29. Guo, J., L. Si, Y. Kong, K. T. Flaherty, X. Xu, Y. Zhu, C. L. Corless, L. Li, H. Li, 
X. Sheng, C. Cui, Z. Chi, S. Li, M. Han, L. Mao, X. Lin, N. Du, X. Zhang, J. Li, 
B. Wang, and S. Qin. 2011. Phase II, open-label, single-arm trial of imatinib 
mesylate in patients with metastatic melanoma harboring c-Kit mutation or 
amplification. J Clin Oncol 29:2904-2909. 
30. McDonnell, K., B. Betz, D. Fullen, and C. D. Lao. 2011. V559A and N822I 
double KIT mutant melanoma with predictable response to imatinib? Pigment 
Cell Melanoma Res 24:390-392. 
31. Woodman, S. E., J. C. Trent, K. Stemke-Hale, A. J. Lazar, S. Pricl, G. M. Pavan, 
M. Fermeglia, Y. N. Gopal, D. Yang, D. A. Podoloff, D. Ivan, K. B. Kim, N. 
Papadopoulos, P. Hwu, G. B. Mills, and M. A. Davies. 2009. Activity of dasatinib 
against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. 
Mol Cancer Ther 8:2079-2085. 
 123 
32. Lim, K. H., A. Pardanani, and A. Tefferi. 2008. KIT and mastocytosis. Acta 
Haematol 119:194-198. 
33. Sotlar, K., T. Marafioti, H. Griesser, J. Theil, C. Aepinus, R. Jaussi, H. Stein, P. 
Valent, and H. P. Horny. 2000. Detection of c-kit mutation Asp 816 to Val in 
microdissected bone marrow infiltrates in a case of systemic mastocytosis 
associated with chronic myelomonocytic leukaemia. Mol Pathol 53:188-193. 
34. Verzijl, A., R. Heide, A. P. Oranje, and R. H. van Schaik. 2007. C-kit Asp-816-
Val mutation analysis in patients with mastocytosis. Dermatology 214:15-20. 
35. Shah, N. P., F. Y. Lee, R. Luo, Y. B. Jiang, M. Donker, and C. Akin. 2006. 
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating 
mutation that triggers neoplastic growth in most patients with systemic 
mastocytosis. Blood 108:286-291. 
36. Tian, Q., H. F. Frierson, Jr., G. W. Krystal, and C. A. Moskaluk. 1999. Activating 
c-kit gene mutations in human germ cell tumors. Am J Pathol 154:1643-1647. 
37. Kemmer, K., C. L. Corless, J. A. Fletcher, L. McGreevey, A. Haley, D. Griffith, 
O. W. Cummings, C. Wait, A. Town, and M. C. Heinrich. 2004. KIT mutations 
are common in testicular seminomas. Am J Pathol 164:305-313. 
38. Boissan, M., F. Feger, J. J. Guillosson, and M. Arock. 2000. c-Kit and c-kit 
mutations in mastocytosis and other hematological diseases. J Leukoc Biol 
67:135-148. 
39. Lombardo, L. J., F. Y. Lee, P. Chen, D. Norris, J. C. Barrish, K. Behnia, S. 
Castaneda, L. A. Cornelius, J. Das, A. M. Doweyko, C. Fairchild, J. T. Hunt, I. 
Inigo, K. Johnston, A. Kamath, D. Kan, H. Klei, P. Marathe, S. Pang, R. Peterson, 
 124 
S. Pitt, G. L. Schieven, R. J. Schmidt, J. Tokarski, M. L. Wen, J. Wityak, and R. 
M. Borzilleri. 2004. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-
hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-
carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent 
antitumor activity in preclinical assays. J Med Chem 47:6658-6661. 
40. Schittenhelm, M. M., S. Shiraga, A. Schroeder, A. S. Corbin, D. Griffith, F. Y. 
Lee, C. Bokemeyer, M. W. Deininger, B. J. Druker, and M. C. Heinrich. 2006. 
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase 
activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms 
associated with human malignancies. Cancer Res 66:473-481. 
41. Burnet, M. 1957. Cancer; a biological approach. I. The processes of control. Br 
Med J 1:779-786. 
42. Liu, Y., and G. Zeng. 2012. Cancer and innate immune system interactions: 
translational potentials for cancer immunotherapy. J Immunother 35:299-308. 
43. Vesely, M. D., M. H. Kershaw, R. D. Schreiber, and M. J. Smyth. 2011. Natural 
innate and adaptive immunity to cancer. Annu Rev Immunol 29:235-271. 
44. Homma, S., H. Komita, Y. Sagawa, T. Ohno, and G. Toda. 2005. Antitumour 
activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-
negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and 
interleukin-12. Immunology 115:451-461. 
45. Quezada, S. A., T. R. Simpson, K. S. Peggs, T. Merghoub, J. Vider, X. Z. Fan, R. 
Blasberg, H. Yagita, P. Muranski, P. A. Antony, N. P. Restifo, and J. P. Allison. 
2010. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate 
 125 
large established melanoma after transfer into lymphopenic hosts. Journal of 
Experimental Medicine 207:637-650. 
46. Xie, Y., A. Akpinarli, C. Maris, E. L. Hipkiss, M. Lane, E. K. Kwon, P. Muranski, 
N. P. Restifo, and P. A. Antony. 2010. Naive tumor-specific CD4(+) T cells 
differentiated in vivo eradicate established melanoma. J Exp Med 207:651-667. 
47. Boon, T., P. G. Coulie, B. J. Van den Eynde, and P. van der Bruggen. 2006. 
Human T cell responses against melanoma. Annu Rev Immunol 24:175-208. 
48. Petrella, T., I. Quirt, S. Verma, A. E. Haynes, M. Charette, and K. Bak. 2007. 
Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic 
review. Cancer Treat Rev 33:484-496. 
49. Rosenberg, S. A., J. C. Yang, D. E. White, and S. M. Steinberg. 1998. Durability 
of complete responses in patients with metastatic cancer treated with high-dose 
interleukin-2: identification of the antigens mediating response. Ann Surg 
228:307-319. 
50. Weber, J. 2007. Review: anti-CTLA-4 antibody ipilimumab: case studies of 
clinical response and immune-related adverse events. Oncologist 12:864-872. 
51. Shablak, A., R. E. Hawkins, D. G. Rothwell, and E. Elkord. 2009. T cell-based 
immunotherapy of metastatic renal cell carcinoma: modest success and future 
perspective. Clin Cancer Res 15:6503-6510. 
52. Schuster, S. J., S. S. Neelapu, B. L. Gause, J. E. Janik, F. M. Muggia, J. P. 
Gockerman, J. N. Winter, C. R. Flowers, D. A. Nikcevich, E. M. Sotomayor, D. S. 
McGaughey, E. S. Jaffe, E. A. Chong, C. W. Reynolds, D. A. Berry, C. F. Santos, 
M. A. Popa, A. M. McCord, and L. W. Kwak. 2011. Vaccination with patient-
 126 
specific tumor-derived antigen in first remission improves disease-free survival in 
follicular lymphoma. J Clin Oncol 29:2787-2794. 
53. Homsi, J., J. C. Grimm, and P. Hwu. 2011. Immunotherapy of melanoma: an 
update. Surg Oncol Clin N Am 20:145-163. 
54. Dudley, M. E., J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. 
Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, L. J. Rogers, 
G. J. Gracia, S. A. Jones, D. P. Mangiameli, M. M. Pelletier, J. Gea-Banacloche, 
M. R. Robinson, D. M. Berman, A. C. Filie, A. Abati, and S. A. Rosenberg. 2005. 
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting 
chemotherapy for the treatment of patients with refractory metastatic melanoma. J 
Clin Oncol 23:2346-2357. 
55. Rosenberg, S. A., and M. E. Dudley. 2004. Cancer regression in patients with 
metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc 
Natl Acad Sci U S A 101 Suppl 2:14639-14645. 
56. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. 
Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, M. R. 
Robinson, M. Raffeld, P. Duray, C. A. Seipp, L. Rogers-Freezer, K. E. Morton, S. 
A. Mavroukakis, D. E. White, and S. A. Rosenberg. 2002. Cancer regression and 
autoimmunity in patients after clonal repopulation with antitumor lymphocytes. 
Science 298:850-854. 
57. Dudley, M. E., J. C. Yang, R. Sherry, M. S. Hughes, R. Royal, U. Kammula, P. F. 
Robbins, J. Huang, D. E. Citrin, S. F. Leitman, J. Wunderlich, N. P. Restifo, A. 
Thomasian, S. G. Downey, F. O. Smith, J. Klapper, K. Morton, C. Laurencot, D. 
 127 
E. White, and S. A. Rosenberg. 2008. Adoptive cell therapy for patients with 
metastatic melanoma: evaluation of intensive myeloablative chemoradiation 
preparative regimens. J Clin Oncol 26:5233-5239. 
58. June, C. H. 2007. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 
117:1466-1476. 
59. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. 
Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, Z. Zheng, A. 
Nahvi, C. R. de Vries, L. J. Rogers-Freezer, S. A. Mavroukakis, and S. A. 
Rosenberg. 2006. Cancer regression in patients after transfer of genetically 
engineered lymphocytes. Science 314:126-129. 
60. Johnson, L. A., R. A. Morgan, M. E. Dudley, L. Cassard, J. C. Yang, M. S. 
Hughes, U. S. Kammula, R. E. Royal, R. M. Sherry, J. R. Wunderlich, C. C. Lee, 
N. P. Restifo, S. L. Schwarz, A. P. Cogdill, R. J. Bishop, H. Kim, C. C. Brewer, S. 
F. Rudy, C. VanWaes, J. L. Davis, A. Mathur, R. T. Ripley, D. A. Nathan, C. M. 
Laurencot, and S. A. Rosenberg. 2009. Gene therapy with human and mouse T-
cell receptors mediates cancer regression and targets normal tissues expressing 
cognate antigen. Blood 114:535-546. 
61. Lo, A. S., Q. Ma, D. L. Liu, and R. P. Junghans. 2010. Anti-GD3 chimeric sFv-
CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma 
and other neuroectodermal tumors. Clin Cancer Res 16:2769-2780. 
62. Burns, W. R., Y. Zhao, T. L. Frankel, C. S. Hinrichs, Z. Zheng, H. Xu, S. A. 
Feldman, S. Ferrone, S. A. Rosenberg, and R. A. Morgan. 2010. A high molecular 
 128 
weight melanoma-associated antigen-specific chimeric antigen receptor redirects 
lymphocytes to target human melanomas. Cancer Res 70:3027-3033. 
63. Peng, W., Y. Ye, B. A. Rabinovich, C. Liu, Y. Lou, M. Zhang, M. Whittington, Y. 
Yang, W. W. Overwijk, G. Lizee, and P. Hwu. 2010. Transduction of tumor-
specific T cells with CXCR2 chemokine receptor improves migration to tumor 
and antitumor immune responses. Clin Cancer Res 16:5458-5468. 
64. Pasquali, S., and S. Mocellin. 2010. The anticancer face of interferon alpha (IFN-
alpha): from biology to clinical results, with a focus on melanoma. Curr Med 
Chem 17:3327-3336. 
65. Malek, T. R. 2008. The biology of interleukin-2. Annu Rev Immunol 26:453-479. 
66. Petrella, T., I. Quirt, S. Verma, A. E. Haynes, M. Charette, and K. Bak. 2007. 
Single-agent interleukin-2 in the treatment of metastatic melanoma. Curr Oncol 
14:21-26. 
67. Eklund, J. W., and T. M. Kuzel. 2004. A review of recent findings involving 
interleukin-2-based cancer therapy. Curr Opin Oncol 16:542-546. 
68. Schwartzentruber, D. J., D. H. Lawson, J. M. Richards, R. M. Conry, D. M. 
Miller, J. Treisman, F. Gailani, L. Riley, K. Conlon, B. Pockaj, K. L. Kendra, R. 
L. White, R. Gonzalez, T. M. Kuzel, B. Curti, P. D. Leming, E. D. Whitman, J. 
Balkissoon, D. S. Reintgen, H. Kaufman, F. M. Marincola, M. J. Merino, S. A. 
Rosenberg, P. Choyke, D. Vena, and P. Hwu. 2011. gp100 peptide vaccine and 
interleukin-2 in patients with advanced melanoma. N Engl J Med 364:2119-2127. 
69. Krummel, M. F., and J. P. Allison. 1995. CD28 and CTLA-4 have opposing 
effects on the response of T cells to stimulation. J Exp Med 182:459-465. 
 129 
70. Chambers, C. A., and J. P. Allison. 1996. The role of tyrosine phosphorylation 
and PTP-1C in CTLA-4 signal transduction. Eur J Immunol 26:3224-3229. 
71. Krummel, M. F., and J. P. Allison. 1996. CTLA-4 engagement inhibits IL-2 
accumulation and cell cycle progression upon activation of resting T cells. J Exp 
Med 183:2533-2540. 
72. Leach, D. R., M. F. Krummel, and J. P. Allison. 1996. Enhancement of antitumor 
immunity by CTLA-4 blockade. Science 271:1734-1736. 
73. Grosso, J. F., and M. N. Jure-Kunkel. 2013. CTLA-4 blockade in tumor models: 
an overview of preclinical and translational research. Cancer Immun 13:5. 
74. Hodi, F. S., S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. 
Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, W. Akerley, A. J. 
van den Eertwegh, J. Lutzky, P. Lorigan, J. M. Vaubel, G. P. Linette, D. Hogg, C. 
H. Ottensmeier, C. Lebbe, C. Peschel, I. Quirt, J. I. Clark, J. D. Wolchok, J. S. 
Weber, J. Tian, M. J. Yellin, G. M. Nichol, A. Hoos, and W. J. Urba. 2010. 
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl 
J Med 363:711-723. 
75. Robert, C., L. Thomas, I. Bondarenko, S. O'Day, D. J. M, C. Garbe, C. Lebbe, J. 
F. Baurain, A. Testori, J. J. Grob, N. Davidson, J. Richards, M. Maio, A. 
Hauschild, W. H. Miller, Jr., P. Gascon, M. Lotem, K. Harmankaya, R. Ibrahim, S. 
Francis, T. T. Chen, R. Humphrey, A. Hoos, and J. D. Wolchok. 2011. 
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N 
Engl J Med 364:2517-2526. 
 130 
76. Watanabe, T., A. Bertoletti, and T. A. Tanoto. 2010. PD-1/PD-L1 pathway and T-
cell exhaustion in chronic hepatitis virus infection. J Viral Hepat 17:453-458. 
77. Iwai, Y., M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, and N. Minato. 2002. 
Involvement of PD-L1 on tumor cells in the escape from host immune system and 
tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99:12293-
12297. 
78. Wu, C., Y. Zhu, J. Jiang, J. Zhao, X. G. Zhang, and N. Xu. 2006. 
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in 
gastric carcinoma and its clinical significance. Acta Histochem 108:19-24. 
79. Thompson, R. H., M. D. Gillett, J. C. Cheville, C. M. Lohse, H. Dong, W. S. 
Webster, K. G. Krejci, J. R. Lobo, S. Sengupta, L. Chen, H. Zincke, M. L. Blute, 
S. E. Strome, B. C. Leibovich, and E. D. Kwon. 2004. Costimulatory B7-H1 in 
renal cell carcinoma patients: Indicator of tumor aggressiveness and potential 
therapeutic target. Proc Natl Acad Sci U S A 101:17174-17179. 
80. Nomi, T., M. Sho, T. Akahori, K. Hamada, A. Kubo, H. Kanehiro, S. Nakamura, 
K. Enomoto, H. Yagita, M. Azuma, and Y. Nakajima. 2007. Clinical significance 
and therapeutic potential of the programmed death-1 ligand/programmed death-1 
pathway in human pancreatic cancer. Clin Cancer Res 13:2151-2157. 
81. Gadiot, J., A. I. Hooijkaas, A. D. Kaiser, H. van Tinteren, H. van Boven, and C. 
Blank. 2011. Overall survival and PD-L1 expression in metastasized malignant 
melanoma. Cancer 117:2192-2201. 
82. Berger, R., R. Rotem-Yehudar, G. Slama, S. Landes, A. Kneller, M. Leiba, M. 
Koren-Michowitz, A. Shimoni, and A. Nagler. 2008. Phase I safety and 
 131 
pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, 
in patients with advanced hematologic malignancies. Clin Cancer Res 14:3044-
3051. 
83. Brahmer, J. R., C. G. Drake, I. Wollner, J. D. Powderly, J. Picus, W. H. Sharfman, 
E. Stankevich, A. Pons, T. M. Salay, T. L. McMiller, M. M. Gilson, C. Wang, M. 
Selby, J. M. Taube, R. Anders, L. Chen, A. J. Korman, D. M. Pardoll, I. Lowy, 
and S. L. Topalian. 2010. Phase I study of single-agent anti-programmed death-1 
(MDX-1106) in refractory solid tumors: safety, clinical activity, 
pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167-3175. 
84. Brahmer, J. R., S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian, P. Hwu, C. 
G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, H. C. Pitot, O. Hamid, S. Bhatia, R. 
Martins, K. Eaton, S. Chen, T. M. Salay, S. Alaparthy, J. F. Grosso, A. J. Korman, 
S. M. Parker, S. Agrawal, S. M. Goldberg, D. M. Pardoll, A. Gupta, and J. M. 
Wigginton. 2012. Safety and activity of anti-PD-L1 antibody in patients with 
advanced cancer. N Engl J Med 366:2455-2465. 
85. Topalian, S. L., F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. 
McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, P. D. 
Leming, D. R. Spigel, S. J. Antonia, L. Horn, C. G. Drake, D. M. Pardoll, L. Chen, 
W. H. Sharfman, R. A. Anders, J. M. Taube, T. L. McMiller, H. Xu, A. J. Korman, 
M. Jure-Kunkel, S. Agrawal, D. McDonald, G. D. Kollia, A. Gupta, J. M. 
Wigginton, and M. Sznol. 2012. Safety, activity, and immune correlates of anti-
PD-1 antibody in cancer. N Engl J Med 366:2443-2454. 
 132 
86. Lipson, E. J., W. H. Sharfman, C. G. Drake, I. Wollner, J. M. Taube, R. A. 
Anders, H. Xu, S. Yao, A. Pons, L. Chen, D. M. Pardoll, J. R. Brahmer, and S. L. 
Topalian. 2013. Durable cancer regression off-treatment and effective reinduction 
therapy with an anti-PD-1 antibody. Clin Cancer Res 19:462-468. 
87. Ruby, C. E., W. L. Redmond, D. Haley, and A. D. Weinberg. 2007. Anti-OX40 
stimulation in vivo enhances CD8+ memory T cell survival and significantly 
increases recall responses. Eur J Immunol 37:157-166. 
88. Gough, M. J., C. E. Ruby, W. L. Redmond, B. Dhungel, A. Brown, and A. D. 
Weinberg. 2008. OX40 agonist therapy enhances CD8 infiltration and decreases 
immune suppression in the tumor. Cancer Research 68:5206-5215. 
89. May, K. F., Jr., L. Chen, P. Zheng, and Y. Liu. 2002. Anti-4-1BB monoclonal 
antibody enhances rejection of large tumor burden by promoting survival but not 
clonal expansion of tumor-specific CD8+ T cells. Cancer Res 62:3459-3465. 
90. Li, B., J. Lin, M. Vanroey, M. Jure-Kunkel, and K. Jooss. 2007. Established B16 
tumors are rejected following treatment with GM-CSF-secreting tumor cell 
immunotherapy in combination with anti-4-1BB mAb. Clin Immunol 125:76-87. 
91. Welniak, L. A., L. Shorts, J. Subleski, B. R. Blazar, R. H. Wiltrout, and W. J. 
Murphy. 2004. Tumor regression by anti-CD40 and interleukin-2: role of CD40 in 
hematopoietic cells and organ-specific effects. Biol Blood Marrow Transplant 
10:534-539. 
92. Dominguez, A. L., and J. Lustgarten. 2010. Targeting the tumor 
microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the 
induction of antitumor immune responses. Vaccine 28:1383-1390. 
 133 
93. Croft, M. 2010. Control of immunity by the TNFR-related molecule OX40 
(CD134). Annu Rev Immunol 28:57-78. 
94. Croft, M., T. So, W. Duan, and P. Soroosh. 2009. The significance of OX40 and 
OX40L to T-cell biology and immune disease. Immunol Rev 229:173-191. 
95. Kopf, M., C. Ruedl, N. Schmitz, A. Gallimore, K. Lefrang, B. Ecabert, B. 
Odermatt, and M. F. Bachmann. 1999. OX40-deficient mice are defective in Th 
cell proliferation but are competent in generating B cell and CTL Responses after 
virus infection. Immunity 11:699-708. 
96. Chen, A. I., A. J. McAdam, J. E. Buhlmann, S. Scott, M. L. Lupher, E. A. 
Greenfield, P. R. Baum, W. C. Fanslow, D. M. Calderhead, G. J. Freeman, and A. 
H. Sharpe. 1999. Ox40-ligand has a critical costimulatory role in dendritic cell: T 
cell interactions. Immunity 11:689-698. 
97. Bansal-Pakala, P., B. S. Halteman, M. H. Y. Cheng, and M. Croft. 2004. 
Costimulation of CD8 T cell responses by OX40. Journal of Immunology 
172:4821-4825. 
98. Soroosh, P., S. Ine, K. Sugamura, and N. Ishii. 2007. Differential requirements for 
OX40 signals on generation of effector and central memory CD4+ T cells. J 
Immunol 179:5014-5023. 
99. Vu, M. D., X. Xiao, W. Gao, N. Degauque, M. Chen, A. Kroemer, N. Killeen, N. 
Ishii, and X. C. Li. 2007. OX40 costimulation turns off Foxp3+ Tregs. Blood 
110:2501-2510. 
 134 
100. Takeda, I., S. Ine, N. Killeen, L. C. Ndhlovu, K. Murata, S. Satomi, K. Sugamura, 
and N. Ishii. 2004. Distinct roles for the OX40-OX40 ligand interaction in 
regulatory and nonregulatory T cells. J Immunol 172:3580-3589. 
101. Valzasina, B., C. Guiducci, H. Dislich, N. Killeen, A. D. Weinberg, and M. P. 
Colombo. 2005. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks 
their inhibitory activity: a novel regulatory role for OX40 and its comparison with 
GITR. Blood 105:2845-2851. 
102. Zaini, J., S. Andarini, M. Tahara, Y. Saijo, N. Ishii, K. Kawakami, M. Taniguchi, 
K. Sugamura, T. Nukiwa, and T. Kikuchi. 2007. OX40 ligand expressed by DCs 
costimulates NKT and CD4+ Th cell antitumor immunity in mice. J Clin Invest 
117:3330-3338. 
103. Liu, C., Y. Lou, G. Lizee, H. Qin, S. Liu, B. Rabinovich, G. J. Kim, Y. H. Wang, 
Y. Ye, A. G. Sikora, W. W. Overwijk, Y. J. Liu, G. Wang, and P. Hwu. 2008. 
Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T 
cell cross-priming and tumor regression in mice. J Clin Invest 118:1165-1175. 
104. Pardee, A. D., D. McCurry, S. Alber, P. Hu, A. L. Epstein, and W. J. Storkus. 
2010. A Therapeutic OX40 Agonist Dynamically Alters Dendritic, Endothelial, 
and T Cell Subsets within the Established Tumor Microenvironment. Cancer 
Research 70:9041-9052. 
105. Ndhlovu, L. C., N. Ishii, K. Murata, T. Sato, and K. Sugamura. 2001. Critical 
involvement of OX40 ligand signals in the T cell priming events during 
experimental autoimmune encephalomyelitis. Journal of Immunology 167:2991-
2999. 
 135 
106. Andarini, S., T. Kikuchi, M. Nukiwa, P. Pradono, T. Suzuki, S. Ohkouchi, A. 
Inoue, M. Maemondo, N. Ishii, Y. Saijo, K. Sugamura, and T. Nukiwa. 2004. 
Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells 
enhances antitumor immunity of tumor-bearing hosts. Cancer Res 64:3281-3287. 
107. Jensen, S. M., L. D. Maston, M. I. Gough, C. E. Ruby, W. L. Redmond, M. 
Crittenden, Y. H. Li, S. Puri, C. H. Poehlein, N. Morris, M. Kovacsovics-
Bankowski, T. Moudgil, C. Twitty, E. B. Walker, H. M. Hu, W. J. Urba, A. D. 
Weinberg, B. Curti, and B. A. Fox. 2010. Signaling Through OX40 Enhances 
Antitumor Immunity. Seminars in Oncology 37:524-532. 
108. Kitamura, N., S. Murata, T. Ueki, E. Mekata, R. T. Reilly, E. M. Jaffee, and T. 
Tani. 2009. OX40 costimulation can abrogate Foxp3(+) regulatory T cell-
mediated suppression of antitumor immunity. International Journal of Cancer 
125:630-638. 
109. Hirschhorn-Cymerman, D., G. A. Rizzuto, T. Merghoub, A. D. Cohen, F. 
Avogadri, A. M. Lesokhin, A. D. Weinberg, J. D. Wolchok, and A. N. Houghton. 
2009. OX40 engagement and chemotherapy combination provides potent 
antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med 
206:1103-1116. 
110. Yokouchi, H., K. Yamazaki, K. Chamoto, S. Oizumi, H. Dosaka-Akita, T. 
Nishimura, and M. Nishimura. 2007. Anti-OX40 monoclonal antibody therapy in 
combination with radiotherapy results in powerful therapeutic antitumor 
immunity to murine lung cancer. J Thorac Oncol 2:S324-S325. 
 136 
111. De Smedt, T., J. Smith, P. Baum, W. Fanslow, E. Butz, and C. Maliszewski. 2002. 
Ox40 costimulation enhances the development of T cell responses induced by 
dendritic cells in vivo. J Immunol 168:661-670. 
112. Kjaergaard, J., L. Peng, P. A. Cohen, J. A. Drazba, A. D. Weinberg, and S. Shu. 
2001. Augmentation versus inhibition: effects of conjunctional OX-40 receptor 
monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced 
tumor. J Immunol 167:6669-6677. 
113. Marincola, F. M., E. M. Jaffee, D. J. Hicklin, and S. Ferrone. 2000. Escape of 
human solid tumors from T-cell recognition: molecular mechanisms and 
functional significance. Adv Immunol 74:181-273. 
114. Rivoltini, L., M. Carrabba, V. Huber, C. Castelli, L. Novellino, P. Dalerba, R. 
Mortarini, G. Arancia, A. Anichini, S. Fais, and G. Parmiani. 2002. Immunity to 
cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 
188:97-113. 
115. Rodriguez, P. C., A. H. Zea, and A. C. Ochoa. 2003. Mechanisms of tumor 
evasion from the immune response. Cancer Chemother Biol Response Modif 
21:351-364. 
116. Rabinovich, G. A., D. Gabrilovich, and E. M. Sotomayor. 2007. 
Immunosuppressive strategies that are mediated by tumor cells. Annual Review 
of Immunology 25:267-296. 
117. Mocellin, S., F. M. Marincola, and H. A. Young. 2005. Interleukin-10 and the 
immune response against cancer: a counterpoint. J Leukoc Biol 78:1043-1051. 
 137 
118. Beck, C., H. Schreiber, and D. Rowley. 2001. Role of TGF-beta in immune-
evasion of cancer. Microsc Res Tech 52:387-395. 
119. Johnson, B. F., T. M. Clay, A. C. Hobeika, H. K. Lyerly, and M. A. Morse. 2007. 
Vascular endothelial growth factor and immunosuppression in cancer: current 
knowledge and potential for new therapy. Expert Opin Biol Th 7:449-460. 
120. Muller, A. J., and G. C. Prendergast. 2007. Indoleamine 2,3-dioxygenase in 
immune suppression and cancer. Curr Cancer Drug Targets 7:31-40. 
121. Munder, M. 2009. Arginase: an emerging key player in the mammalian immune 
system. Br J Pharmacol 158:638-651. 
122. Zou, W. P. 2005. Immunosuppressive networks in the tumour environment and 
their therapeutic relevance. Nature Reviews Cancer 5:263-274. 
123. Whiteside, T. L. 2006. Immune suppression in cancer: effects on immune cells, 
mechanisms and future therapeutic intervention. Semin Cancer Biol 16:3-15. 
124. Sakthivel, P., M. Gereke, and D. Bruder. 2012. Therapeutic intervention in cancer 
and chronic viral infections: antibody mediated manipulation of PD-1/PD-L1 
interaction. Rev Recent Clin Trials 7:10-23. 
125. Wajant, H. 2006. CD95L/FasL and TRAIL in tumour surveillance and cancer 
therapy. Cancer Treat Res 130:141-165. 
126. Villa-Morales, M., and J. Fernandez-Piqueras. 2012. Targeting the Fas/FasL 
signaling pathway in cancer therapy. Expert Opin Ther Targets 16:85-101. 
127. Yang, Y., G. Lizee, and P. Hwu. 2013. Strong emerging rationale for combining 
oncogene-targeted agents with immunotherapy. Oncoimmunology 2:e22730. 
 138 
128. Balachandran, V. P., M. J. Cavnar, S. Zeng, Z. M. Bamboat, L. M. Ocuin, H. 
Obaid, E. C. Sorenson, R. Popow, C. Ariyan, F. Rossi, P. Besmer, T. Guo, C. R. 
Antonescu, T. Taguchi, J. Yuan, J. D. Wolchok, J. P. Allison, and R. P. Dematteo. 
2011. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal 
tumor through the inhibition of Ido. Nat Med 17:1094-1100. 
129. Khalili, J. S., S. Liu, T. G. Rodriguez-Cruz, M. Whittington, S. Wardell, C. Liu, 
M. Zhang, Z. A. Cooper, D. T. Frederick, Y. Li, R. W. Joseph, C. Bernatchez, S. 
Ekmekcioglu, E. Grimm, L. G. Radvanyi, R. E. Davis, M. A. Davies, J. A. Wargo, 
P. Hwu, and G. Lizee. 2012. Oncogenic BRAF(V600E) promotes stromal cell-
mediated immunosuppression via induction of interleukin-1 in melanoma. Clin 
Cancer Res 18:5329-5340. 
130. Ko, J. S., A. H. Zea, B. I. Rini, J. L. Ireland, P. Elson, P. Cohen, A. Golshayan, P. 
A. Rayman, L. Wood, J. Garcia, R. Dreicer, R. Bukowski, and J. H. Finke. 2009. 
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in 
renal cell carcinoma patients. Clin Cancer Res 15:2148-2157. 
131. Galluzzi, L., L. Senovilla, L. Zitvogel, and G. Kroemer. 2012. The secret ally: 
immunostimulation by anticancer drugs. Nat Rev Drug Discov 11:215-233. 
132. Apetoh, L., F. Ghiringhelli, A. Tesniere, M. Obeid, C. Ortiz, A. Criollo, G. 
Mignot, M. C. Maiuri, E. Ullrich, P. Saulnier, H. Yang, S. Amigorena, B. Ryffel, 
F. J. Barrat, P. Saftig, F. Levi, R. Lidereau, C. Nogues, J. P. Mira, A. Chompret, 
V. Joulin, F. Clavel-Chapelon, J. Bourhis, F. Andre, S. Delaloge, T. Tursz, G. 
Kroemer, and L. Zitvogel. 2007. Toll-like receptor 4-dependent contribution of 
 139 
the immune system to anticancer chemotherapy and radiotherapy. Nature 
Medicine 13:1050-1059. 
133. Mattarollo, S. R., S. Loi, H. Duret, Y. Ma, L. Zitvogel, and M. J. Smyth. 2011. 
Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of 
established tumors. Cancer Res 71:4809-4820. 
134. Robbins, P. F., M. El-Gamil, Y. F. Li, Y. Kawakami, D. Loftus, E. Appella, and S. 
A. Rosenberg. 1996. A mutated beta-catenin gene encodes a melanoma-specific 
antigen recognized by tumor infiltrating lymphocytes. J Exp Med 183:1185-1192. 
135. Theobald, M., J. Biggs, D. Dittmer, A. J. Levine, and L. A. Sherman. 1995. 
Targeting p53 as a general tumor antigen. P Natl Acad Sci USA 92:11993-11997. 
136. Segal, N. H., D. W. Parsons, K. S. Peggs, V. Velculescu, K. W. Kinzler, B. 
Vogelstein, and J. P. Allison. 2008. Epitope landscape in breast and colorectal 
cancer. Cancer Res 68:889-892. 
137. Schade, A. E., G. L. Schieven, R. Townsend, A. M. Jankowska, V. Susulic, R. 
Zhang, H. Szpurka, and J. P. Maciejewski. 2008. Dasatinib, a small-molecule 
protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. 
Blood 111:1366-1377. 
138. Fraser, C. K., S. J. Blake, K. R. Diener, A. B. Lyons, M. P. Brown, T. P. Hughes, 
and J. D. Hayball. 2009. Dasatinib inhibits recombinant viral antigen-specific 
murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro 
and in vivo. Exp Hematol 37:256-265. 
 140 
139. Fei, F., Y. Z. Yu, A. Schmitt, M. T. Rojewski, B. O. Chen, M. Gotz, H. Dohner, 
D. Bunjes, and M. Schmitt. 2009. Dasatinib inhibits the proliferation and function 
of CD4(+)CD25(+) regulatory T cells. Brit J Haematol 144:195-205. 
140. Watanabe, S., K. Deguchi, R. Zheng, H. Tamai, L. X. Wang, P. A. Cohen, and S. 
Shu. 2008. Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell 
sensitization in tumor-draining lymph nodes. J Immunol 181:3291-3300. 
141. Youn, J. I., S. Nagaraj, M. Collazo, and D. I. Gabrilovich. 2008. Subsets of 
myeloid-derived suppressor cells in tumor-bearing mice. Journal of Immunology 
181:5791-5802. 
142. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as 
regulators of the immune system. Nature Reviews Immunology 9:162-174. 
143. Kao, J., E. C. Ko, S. Eisenstein, A. G. Sikora, S. Fu, and S. H. Chen. 2011. 
Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit 
Rev Oncol Hematol 77:12-19. 
144. Sumimoto, H., F. Imabayashi, T. Iwata, and Y. Kawakami. 2006. The BRAF-
MAPK signaling pathway is essential for cancer-immune evasion in human 
melanoma cells. J Exp Med 203:1651-1656. 
145. Lucas, M., X. Zhang, V. Prasanna, and D. M. Mosser. 2005. ERK activation 
following macrophage FcgammaR ligation leads to chromatin modifications at 
the IL-10 locus. J Immunol 175:469-477. 
146. Bailey, D. P., M. Kashyap, L. A. Bouton, P. J. Murray, and J. J. Ryan. 2006. 
Interleukin-10 induces apoptosis in developing mast cells and macrophages. J 
Leukoc Biol 80:581-589. 
 141 
147. Weichsel, R., C. Dix, L. Wooldridge, M. Clement, A. Fenton-May, A. K. Sewell, 
J. Zezula, E. Greiner, E. Gostick, D. A. Price, H. Einsele, and R. Seggewiss. 2008. 
Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin 
Cancer Res 14:2484-2491. 
148. Mustjoki, S., M. Ekblom, T. P. Arstila, I. Dybedal, P. K. Epling-Burnette, F. 
Guilhot, H. Hjorth-Hansen, M. Hoglund, P. Kovanen, T. Laurinolli, J. Liesveld, R. 
Paquette, J. Pinilla-Ibarz, A. Rauhala, N. Shah, B. Simonsson, M. Sinisalo, J. L. 
Steegmann, L. Stenke, and K. Porkka. 2009. Clonal expansion of T/NK-cells 
during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23:1398-1405. 
149. de Lavallade, H., S. Punnialingam, D. Milojkovic, M. Bua, J. S. Khorashad, I. H. 
Gabriel, A. Chaidos, E. Olavarria, J. M. Goldman, J. F. Apperley, and D. Marin. 
2008. Pleural effusions in patients with chronic myeloid leukaemia treated with 
dasatinib may have an immune-mediated pathogenesis. Brit J Haematol 141:745-
747. 
150. Das Thakur, M., F. Salangsang, A. S. Landman, W. R. Sellers, N. K. Pryer, M. P. 
Levesque, R. Dummer, M. McMahon, and D. D. Stuart. 2013. Modelling 
vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. 
Nature 494:251-255. 
151. Shah, N. P., C. Kasap, C. Weier, M. Balbas, J. M. Nicoll, E. Bleickardt, C. 
Nicaise, and C. L. Sawyers. 2008. Transient potent BCR-ABL inhibition is 
sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. 
Cancer Cell 14:485-493. 
 142 
152. Kepp, O., A. Tesniere, F. Schlemmer, M. Michaud, L. Senovilla, L. Zitvogel, and 
G. Kroemer. 2009. Immunogenic cell death modalities and their impact on cancer 
treatment. Apoptosis 14:364-375. 
153. Tesniere, A., L. Apetoh, F. Ghiringhelli, N. Joza, T. Panaretakis, O. Kepp, F. 
Schlemmer, L. Zitvogel, and G. Kroemer. 2008. Immunogenic cancer cell death: 
a key-lock paradigm. Curr Opin Immunol 20:504-511. 
154. Zitvogel, L., O. Kepp, L. Senovilla, L. Menger, N. Chaput, and G. Kroemer. 2010. 
Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin 
exposure pathway. Clin Cancer Res 16:3100-3104. 
155. Kepp, O., L. Galluzzi, I. Martins, F. Schlemmer, S. Adjemian, M. Michaud, A. Q. 
Sukkurwala, L. Menger, L. Zitvogel, and G. Kroemer. 2011. Molecular 
determinants of immunogenic cell death elicited by anticancer chemotherapy. 
Cancer Metastasis Rev 30:61-69. 
156. Chaput, N., S. De Botton, M. Obeid, L. Apetoh, F. Ghiringhelli, T. Panaretakis, C. 
Flament, L. Zitvogel, and G. Kroemer. 2007. Molecular determinants of 
immunogenic cell death: surface exposure of calreticulin makes the difference. J 
Mol Med (Berl) 85:1069-1076. 
157. Ray, P., N. Krishnamoorthy, T. B. Oriss, and A. Ray. 2010. Signaling of c-kit in 
dendritic cells influences adaptive immunity. Ann N Y Acad Sci 1183:104-122. 
158. Appel, S., A. M. Boehmler, F. Grunebach, M. R. Muller, A. Rupf, M. M. Weck, 
U. Hartmann, V. L. Reichardt, L. Kanz, T. H. Brummendorf, and P. Brossart. 
2004. Imatinib mesylate affects the development and function of dendritic cells 
generated from CD34+ peripheral blood progenitor cells. Blood 103:538-544. 
 143 
159. Appel, S., A. Rupf, M. M. Weck, O. Schoor, T. H. Brummendorf, T. Weinschenk, 
F. Grunebach, and P. Brossart. 2005. Effects of imatinib on monocyte-derived 
dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt 
signaling pathways. Clin Cancer Res 11:1928-1940. 
160. Sakaguchi, S., R. Setoguchi, H. Yagi, and T. Nomura. 2006. Naturally arising 
Foxp3-expressing CD25+CD4+ regulatory T cells in self-tolerance and 
autoimmune disease. Curr Top Microbiol Immunol 305:51-66. 
161. Sakaguchi, S. 2005. Naturally arising Foxp3-expressing CD25+CD4+ regulatory 
T cells in immunological tolerance to self and non-self. Nat Immunol 6:345-352. 
162. Sakaguchi, S. 2004. Naturally arising CD4+ regulatory t cells for immunologic 
self-tolerance and negative control of immune responses. Annu Rev Immunol 
22:531-562. 
163. Schmidt, A., N. Oberle, and P. H. Krammer. 2012. Molecular mechanisms of 
treg-mediated T cell suppression. Front Immunol 3:51. 
164. Vignali, D. A. A., L. W. Collison, and C. J. Workman. 2008. How regulatory T 
cells work. Nature Reviews Immunology 8:523-532. 
165. Sojka, D. K., Y. H. Huang, and D. J. Fowell. 2008. Mechanisms of regulatory T-
cell suppression - a diverse arsenal for a moving target. Immunology 124:13-22. 
166. Badoual, C., S. Hans, W. H. Fridman, D. Brasnu, S. Erdman, and E. Tartour. 2009. 
Revisiting the prognostic value of regulatory T cells in patients with cancer. J Clin 
Oncol 27:e5-6; author reply e7. 
167. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-
Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, Y. Zhu, S. Wei, I. Kryczek, B. 
 144 
Daniel, A. Gordon, L. Myers, A. Lackner, M. L. Disis, K. L. Knutson, L. Chen, 
and W. Zou. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma 
fosters immune privilege and predicts reduced survival. Nat Med 10:942-949. 
168. Gao, Q., S. J. Qiu, J. Fan, J. Zhou, X. Y. Wang, Y. S. Xiao, Y. Xu, Y. W. Li, and 
Z. Y. Tang. 2007. Intratumoral balance of regulatory and cytotoxic T cells is 
associated with prognosis of hepatocellular carcinoma after resection. J Clin 
Oncol 25:2586-2593. 
169. Kelley, T. W., B. Pohlman, P. Elson, and E. D. Hsi. 2007. The ratio of FOXP3+ 
regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in 
classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. 
Am J Clin Pathol 128:958-965. 
170. Perrone, G., P. A. Ruffini, V. Catalano, C. Spino, D. Santini, P. Muretto, C. Spoto, 
C. Zingaretti, V. Sisti, P. Alessandroni, P. Giordani, A. Cicetti, S. D'Emidio, S. 
Morini, A. Ruzzo, M. Magnani, G. Tonini, C. Rabitti, and F. Graziano. 2008. 
Intratumoural FOXP3-positive regulatory T cells are associated with adverse 
prognosis in radically resected gastric cancer. Eur J Cancer 44:1875-1882. 
171. Xu, L., W. Xu, S. Qiu, and S. Xiong. 2010. Enrichment of CCR6+Foxp3+ 
regulatory T cells in the tumor mass correlates with impaired CD8+ T cell 
function and poor prognosis of breast cancer. Clin Immunol 135:466-475. 
172. Liotta, F., M. Gacci, F. Frosali, V. Querci, G. Vittori, A. Lapini, V. Santarlasci, S. 
Serni, L. Cosmi, L. Maggi, R. Angeli, B. Mazzinghi, P. Romagnani, E. Maggi, M. 
Carini, S. Romagnani, and F. Annunziato. 2011. Frequency of regulatory T cells 
 145 
in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor 
prognosis in renal cell carcinoma. BJU Int 107:1500-1506. 
173. Shenghui, Z., H. Yixiang, W. Jianbo, Y. Kang, B. Laixi, Z. Yan, and X. Xi. 2011. 
Elevated frequencies of CD4(+) CD25(+) CD127lo regulatory T cells is 
associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer 
129:1373-1381. 
174. Shevach, E. M. 2002. CD4+ CD25+ suppressor T cells: more questions than 
answers. Nat Rev Immunol 2:389-400. 
175. Kim, J. K., M. Klinger, J. Benjamin, Y. Xiao, D. J. Erle, D. R. Littman, and N. 
Killeen. 2009. Impact of the TCR signal on regulatory T cell homeostasis, 
function, and trafficking. PLoS One 4:e6580. 
176. Larmonier, N., N. Janikashvili, C. J. LaCasse, C. B. Larmonier, J. Cantrell, E. 
Situ, T. Lundeen, B. Bonnotte, and E. Katsanis. 2008. Imatinib mesylate inhibits 
CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy 
against BCR-ABL- tumors. J Immunol 181:6955-6963. 
177. Cabrera, R., M. Ararat, Y. Xu, T. Brusko, C. Wasserfall, M. A. Atkinson, L. J. 
Chang, C. Liu, and D. R. Nelson. 2013. Immune modulation of effector CD4+ 
and regulatory T cell function by sorafenib in patients with hepatocellular 
carcinoma. Cancer Immunol Immunother 62:737-746. 
178. Seggewiss, R., D. A. Price, and M. A. Purbhoo. 2008. Immunomodulatory effects 
of imatinib and second-generation tyrosine kinase inhibitors on T cells and 
dendritic cells: an update. Cytotherapy 10:633-641. 
 146 
179. Sato, T., P. McCue, K. Masuoka, S. Salwen, E. C. Lattime, M. J. Mastrangelo, 
and D. Berd. 1996. Interleukin 10 production by human melanoma. Clin Cancer 
Res 2:1383-1390. 
180. O'Hara, R. J., J. Greenman, A. W. MacDonald, K. M. Gaskell, K. P. Topping, G. 
S. Duthie, M. J. Kerin, P. W. R. Lee, and J. R. T. Monson. 1998. Advanced 
colorectal cancer is associated with impaired interleukin 12 and enhanced 
interleukin 10 production. Clinical Cancer Research 4:1943-1948. 
181. Nacinovic-Duletic, A., S. Stifter, S. Dvornik, Z. Skunca, and N. Jonjic. 2008. 
Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features 
and prognosis in patients with diffuse large B-cell lymphoma. Int J Lab Hematol 
30:230-239. 
182. Stanilov, N., L. Miteva, T. Deliysky, J. Jovchev, and S. Stanilova. 2010. 
Advanced Colorectal Cancer Is Associated With Enhanced IL-23 and IL-10 
Serum Levels. Labmedicine 41:159-163. 
183. Mahipal, A., M. Terai, D. Berd, I. Chervoneva, K. Patel, M. J. Mastrangelo, and T. 
Sato. 2011. Tumor-derived interleukin-10 as a prognostic factor in stage III 
patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. 
Cancer Immunol Immun 60:1039-1045. 
184. Kim, Y. J., S. J. Park, and H. E. Broxmeyer. 2011. Phagocytosis, a potential 
mechanism for myeloid-derived suppressor cell regulation of CD8+ T cell 
function mediated through programmed cell death-1 and programmed cell death-1 
ligand interaction. J Immunol 187:2291-2301. 
 147 
185. Mocellin, S., F. Marincola, C. R. Rossi, D. Nitti, and M. Lise. 2004. The 
multifaceted relationship between IL-10 and adaptive immunity: putting together 
the pieces of a puzzle. Cytokine Growth F R 15:61-76. 
186. Steinbrink, K., E. Graulich, S. Kubsch, J. Knop, and A. H. Enk. 2002. CD4(+) 
and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic 
cells display antigen-specific suppressor activity. Blood 99:2468-2476. 
187. Yue, F. Y., R. Dummer, R. Geertsen, G. Hofbauer, E. Laine, S. Manolio, and G. 
Burg. 1997. Interleukin-10 is a growth factor for human melanoma cells and 
down-regulates HLA class-1, HLA class-II and ICAM-1 molecules. International 
Journal of Cancer 71:630-637. 
188. Kurte, M., M. Lopez, A. Aguirre, A. Escobar, J. C. Aguillon, J. Charo, C. G. 
Larsen, R. Kiessling, and F. Salazar-Onfray. 2004. A synthetic peptide 
homologous to functional domain of human IL-10 down-regulates expression of 
MHC class I and transporter associated with antigen processing 1/2 in human 
melanoma cells. Journal of Immunology 173:1731-1737. 
189. Taga, K., and G. Tosato. 1992. IL-10 inhibits human T cell proliferation and IL-2 
production. J Immunol 148:1143-1148. 
190. Cottrez, F., and H. Groux. 2001. Regulation of TGF-beta response during T cell 
activation is modulated by IL-10. J Immunol 167:773-778. 
191. Akbari, O., R. H. DeKruyff, and D. T. Umetsu. 2001. Pulmonary dendritic cells 
producing IL-10 mediate tolerance induced by respiratory exposure to antigen. 
Nature Immunology 2:725-731. 
 148 
192. Roncarolo, M. G., R. Bacchetta, C. Bordignon, S. Narula, and M. K. Levings. 
2001. Type 1 T regulatory cells. Immunol Rev 182:68-79. 
193. Urosevic, M., and R. Dummer. 2003. HLA-G and IL-10 expression in human 
cancer--different stories with the same message. Semin Cancer Biol 13:337-342. 
194. Song, M., D. Chen, B. Lu, C. Wang, J. Zhang, L. Huang, X. Wang, C. L. 
Timmons, J. Hu, B. Liu, X. Wu, L. Wang, J. Wang, and H. Liu. 2013. PTEN Loss 
Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 
Expression and Clinical Parameters in Colorectal Cancer. PLoS One 8:e65821. 
195. Jiang, X., J. Zhou, A. Giobbie-Hurder, J. Wargo, and F. S. Hodi. 2013. The 
activation of MAPK in melanoma cells resistant to BRAF inhibition promotes 
PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer 
Res 19:598-609. 
196. Kortylewski, M., and H. Yu. 2008. Role of Stat3 in suppressing anti-tumor 
immunity. Current Opinion in Immunology 20:228-233. 
197. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: 
moving beyond current vaccines. Nat Med 10:909-915. 
198. Naito, Y., K. Saito, K. Shiiba, A. Ohuchi, K. Saigenji, A. Nagura, and H. Ohtani. 
1998. CD8(+) T cells infiltrated within cancer cell nests as a prognostic factor in 
human colorectal cancer. Cancer Research 58:3491-3494. 
199. Clemente, C. G., M. C. Mihm, Jr., R. Bufalino, S. Zurrida, P. Collini, and N. 
Cascinelli. 1996. Prognostic value of tumor infiltrating lymphocytes in the 
vertical growth phase of primary cutaneous melanoma. Cancer 77:1303-1310. 
 149 
200. Ogawa, N., L. Ping, L. Zhenjun, Y. Takada, and S. Sugai. 2002. Involvement of 
the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-
inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma 
(CXCL9), in the salivary gland lesions of patients with Sjogren's syndrome. 
Arthritis Rheum 46:2730-2741. 
201. Bonacchi, A., P. Romagnani, R. G. Romanelli, E. Efsen, F. Annunziato, L. 
Lasagni, M. Francalanci, M. Serio, G. Laffi, M. Pinzani, P. Gentilini, and F. 
Marra. 2001. Signal transduction by the chemokine receptor CXCR3: activation 
of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration 
and proliferation in human vascular pericytes. J Biol Chem 276:9945-9954. 
202. Liu, C. W., W. Y. Peng, C. Y. Xu, Y. Y. Lou, M. Y. Zhang, J. A. Wargo, J. Q. 
Chen, H. Y. S. Li, S. S. Watowich, Y. Yang, D. T. Frederick, Z. A. Cooper, R. M. 
Mbofung, M. Whittington, K. T. Flaherty, S. E. Woodman, M. A. Davies, L. G. 
Radvanyi, W. W. Overwijk, G. Lizee, and P. Hwu. 2013. BRAF Inhibition 
Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of 
Adoptive Immunotherapy in Mice. Clinical Cancer Research 19:393-403. 
203. Chen, L. L., X. Chen, H. Choi, H. Sang, L. C. Chen, H. Zhang, L. Gouw, R. H. 
Andtbacka, B. K. Chan, C. K. Rodesch, A. Jimenez, P. Cano, K. A. Jones, C. O. 
Oyedeji, T. Martins, H. R. Hill, J. Schumacher, C. Willmore, C. L. Scaife, J. H. 
Ward, K. Morton, R. Lor Randall, A. J. Lazar, S. Patel, J. C. Trent, M. L. Frazier, 
P. Lin, P. Jensen, and R. S. Benjamin. 2012. Exploiting antitumor immunity to 
overcome relapse and improve remission duration. Cancer Immunol Immunother 
61:1113-1124. 
 150 
Vita 
 
Yan Yang was born in Tangshan, P.R.China on July. 4th, 1984, the daughter of Dr. Fang 
Yang and Dr. Meiyuan Shi. She was enrolled in the 8-year MD program at the Peking 
University Health Science Center in Beijing, P.R.China in September of 2003. After 
completing Bachelor of Clinical Medicine, she attended the MD/PhD joint educational 
program between the University of Texas M.D. Anderson Cancer Center and Peking 
University Health Science Center, in January of 2009. Yan carried out this dissertation 
work in the Department of Melanoma Medical Oncology at the University of Texas M.D. 
Anderson Cancer Center under the guidance of Dr. Patrick Hwu, MD.  
 
Publications 
 
Yang Y, Lizee G, Hwu P. Strong emerging rationale for combining oncogene-targeted 
agents with immunotherapy. Oncoimmunology. 2013 Feb 1;2(2):e22730. 
 
Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, 
Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, 
Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Lizée G, Hwu P . BRAF 
inhibition increases tumor infiltration by T cells and enhances the antitumor activity of 
adoptive immunotherapy in mice. Clinical Cancer Research. 2013 Jan 15;19(2):393-403. 
 
 151 
Yang Y, Liu C, Peng W, Lizee G, Overwijk WW, Woodman S, Hwu P. The antitumor T 
cell response plays a critical role in the therapeutic effects of dasatinib on c-kit mutant 
P815 mastocytoma and can be potentiated by anti-OX40 antibody. Blood. 2012 Nov 29; 
120(23): 4533-43. 
 
Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Overwijk WW, Lizee G, Laszlo R, Hwu 
P. PD-1 blockade enhances T cell migration to tumors through induction of IFN-γ  
inducible chemokines. Cancer Research . 2012 Oct 15;72(20):5209-18. 
 
Liu C, Lewis CM, Lou Y, Xu C, Peng W, Yang Y, Gelbard AH, Lizee G, Zhou D, 
Overwijk WW, Hwu P. Agonistic antibody to CD40 boosts the antitumor activity of 
adoptively transferred T cells in vivo. Journal of Immunotherapy. 2012 Apr; 35(3): 276-
82. 
 
Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, Whittington M, Yang Y, 
Overwijk WW, Lizee G, Hwu P. Transduction of tumor-specific T cells with CXCR2 
chemokine receptor improves migration to tumor and antitumor immune responses. 
Clinical Cancer Research. 2010 Nov; 16(22): 5458-68.  
 
Yang F, Ma W, Luo L, Yang Y, Liu L, Wu F, Wang X, Wang R, Zhang L, Pei X. 
Regulation effect of AcSDKP on cardiac fibroblasts and collagen metabolism mediated 
by TGF-β1   in   rats.   Chinese   Journal   of   Evidence-based Cardiovascular Medicine. 2009 
June;1(3):173-6.  
 152 
 
 
Zhang L, Ma W, Yang Y, Wang R, Chen P, Yan J, Li Q, Li D, Yang F. AcSDKP 
attenuates PDGF-induced cardiac fibroblasts proliferation and collagen expression: role 
of extracellular regulated protein kinase 1/2 pathway. Chinese Journal of cardiovascular 
diseases. 2008 May; 36(5): 444-8. 
 
Li D, Yan J, Luo L, Wu K, Zhang L, Wang R, Yang Y, Yang F. Effect of AcSDKP on 
the Expression of TGF-β1  and  SMAD7  in  Lung  of  Rats  with  Silicosis.  Chinese  Journal  of  
Anatomy. 2008 Apr; 31(4): 235-7.  
 
Wu F, Yang F, Wang X, Liu L, Yang Y, Wang R, Ma W, Luo L, Hu W, Pei X, Zhang L. 
Effect of AcSDKP on the collagen synthesis and expression in cultured rat cardiac 
fibroblasts mediated by Transforming Growth Factor beta-1. Acta Anatomica Sinica. 
2007 Jun; 38(6): 708-12. 
 
Zhang L, Li Q, Chen P, Yan J, Wang R, Yang Y, Yang F. Mediating effect of 
extracellular signal-regulated kinase 1/2 in PDGF-induced proliferation and collagen 
synthesis of cultured rat cardiac fibroblasts. Chinese Journal of Anatomy. 2007 Apr; 
30(4): 416-9. 
